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The role of NAD(P)H:quinone oxidoreductase 1 in non-small cell lung cancer 




     Lung cancer is the leading cause of cancer related deaths worldwide. The five-year 
survival rates for those patients suffering from non-small cell lung cancer (NSCLC), 
continues to be an abysmal 15%. One of the major reasons for the poor survival rate 
amongst NSCLC patients is the lack of early detection and subsequent late stage initial 
diagnosis. Tumors discovered at later stages are often refractory toward chemotherapy 
and radiation regimens. One theory as to why tumors become resistant to therapy relies 
heavily on the cells that make up the cancer stem cell (CSC) niche. This small 
percentage of cells within the heterogeneous tumor has been reported to be responsible 
for drug resistance, tumor recurrence, and metastasis. In general, CSCs have been 
isolated using a number of different markers, including cluster differentiation markers, 
somatic stem cell markers, as well as a number of functional markers such as the side 
population and aldehyde dehydrogenase (ALDH) activity. While some cancer types, 
such as breast and hematologic cancers, have been significantly investigated to identify 
and define their CSC population, lung cancer researchers have only recently begun to 
identify CSC markers in lung tumors. In addition to the CSC population, malignant cells 
can also alter their expression of a number of cytoprotective genes that promote 
tumorigenesis. NAD(P)H:quinone oxidoreductase 1 (NQO1) is a detoxifying enzyme 
that has been demonstrated to be highly overexpressed in a number of different 
malignancies. This overexpression has been utilized as a drug target, as the enzyme is 
expressed at low levels in normal tissue. To this point, there has been success in using 
NQO1 as a drug target, however little research has been conducted on understanding 
why NQO1 is overexpressed in these malignancies. The work presented here 
investigated the role of NQO1 in tumorigenesis as well as its role in maintaining the 
CSC population in NSCLC. We demonstrate that NQO1 promotes anchorage-
independent growth, invasion, reactive oxygen species regulation, anoikis resistance, 
proliferation, in vivo tumor growth, survival, and ALDH activity. Secondly, we 
demonstrate that NQO1 also promotes spheroid formation, both in initial and serial 
contexts, enhances the CSC frequency, and protects spheroid-cultured cells from 
chemotherapy. Finally, we provide preliminary data that indicates that NQO1 mRNA 
may be playing an important signaling role in the promotion of the CSC phenotype. This 
was demonstrated by CRISPR-Cas9 genetic knockout of NQO1 that resulted in a 
reemergence of the CSC phenotype that can be reversed with transient knockdown of 
NQO1 mRNA. In summary, our data demonstrate that NQO1 is playing a vital role in the 
promotion of NSCLC tumorigenesis, as well as supporting the cancer stem cell 
population. Interestingly, these results may be due to a novel signaling mechanism by 
NQO1 mRNA, and not the enzyme itself. Further research will be needed to completely 
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     Lung cancer is the leading cause of cancer related death in the world (1). It is 
predicted to be responsible for more than 158,000 deaths in the United States in the 
year 2015 alone (2). In addition, the disease claims a greater number of lives than 
breast, prostate, and colon cancer combined. Lung cancer is classified into two 
histologically different categories, small cell lung cancer (SCLC) and non-small cell lung 
cancer (NSCLC).  SCLC arises from a neuroendocrine origin, and occurs at a rate of 
20% of all lung malignancies. These tumors are often more aggressive than their 
NSCLC counterparts, resulting in 5-year survival rates of less than 5% versus 15% seen 
in NSCLC (3, 4). The survival rates vary greatly depending on the stage at which the 
cancer is detected, but often patients with SCLC present with advanced and 
disseminated disease leading to an overall increase in mortality (5).  
 
     NSCLC is the most common type of lung cancer in the word, accounting for ~80% of 
all lung cancer cases (6). NSCLC arises from the epithelial cell population within the 
lung and can be further divided into three subcategories based on histological 
assessment. Areas of keratinization and the presence of inflammatory components 
define the first subtype of NSCLC, squamous cell carcinoma. Adenocarcinoma is 
defined by the presence of glandular structures, or solid growths exhibiting mucin 
production. This subtype also tends to be found in the periphery of the lung, where 
squamous cell carcinoma typically originates near the bronchus. The histological 
distinction of the third NSCLC subtype, large cell carcinoma, is decidedly more vague. 
Cases lacking the defining features of squamous cell carcinoma or adenocarcinoma 
tend to be classified as large cell carcinoma (7, 8). While it is possible to histologically 
differentiate each tumor type, these distinctions provide little information on the 
likelihood of recurrence, drug resistance, and metastatic capabilities of the cells. 
Currently, it has become an area of great interest to determine the overall cellular 
makeup of each tumor and define certain niches of cells that exist within, in order to 
improve therapeutic approaches and patient outcomes. 
 
     Recently, the nearly 50-year-old hypothesis that cancer arises from a small 
population of tumor initiating, or cancer stem cells (CSCs) has begun to once again 
grab the attention of researchers (9). The belief is based on the premise of somatic 
stem cells and their unique abilities. It is well known that somatic stem cells are crucial 
for growth, differentiation, and repair of the normal tissues. They achieve these affects 
by providing an unending supply of progenitor cells, while retaining the parental stem 
cell population through asymmetric division (10). Adopting these traits, it is now believed 
that cancers are capable of sustaining growth and promoting recurrence due to the 
presence of a cancer stem cell (CSC) population. These cells harbor the ability to self-
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renew and give rise to progeny that are then able to differentiate into all cell types 
necessary to constitute the complete makeup of a tumor.  
 
     Interestingly, it has also been demonstrated there exists an inherent plasticity in 
transformed cells. Differentiated cancer cells possess the ability to return to their less 
differentiated CSC phenotype as well revert back, thus indicating a divergence from 
regulated somatic cell differentiation (11, 12). Nevertheless, this CSC population 
appears to mediate resistance to therapy, making them difficult to eliminate (13-15). 
This poses an obvious challenge in the treatment of cancer and in fact, therapies have 
been shown to select for the more aggressive CSC phenotype, through the elimination 
of the non-stem cell population (16-18). In addition to therapeutic resistance, the CSC 
population has displayed enhanced capabilities in the processes of degradation, 
invasion, and metastasis in comparison to their non-stem cell counterparts present 
within a malignancy (14, 19, 20).  
 
     Due to CSCs abilities to reconstitute the entire heterogeneous makeup of a tumor, 
their resistance to standard therapies, and demonstration of an increase in the ability to 
metastasize to distant sites, a great amount of research has been directed at defining 
this population in NSCLC. Elucidating this population will have great implications in both 
the diagnostic and therapeutic aspects of cancer therapy. However, this approach is 
made difficult by the elusiveness of the CSC population within the heterogeneous 
population, since they can constitute as little as five percent of the total cell population. 
This percentage however, can vary depending on the selection marker or method (21). 
Currently, research is focused on a number characteristics thought to be correlative to 
the CSC population, including specific cluster differentiation (CD) markers, efflux 
pumps, detoxifying mechanisms, and stem cell signaling pathways. In order to 
understand the importance of the 
cancer stem cell population and its 
implications to prognosis, 
therapeutic resistance, recurrence, 
and the future of drug design, it is 
first necessary to understand the 
concept of the cancer stem cell 
hypothesis and those markers used 
to define this elusive population. 
 
The Cancer Stem Cell Hypothesis 
 
     The cancer stem cell hypothesis 
originated more than 50 years ago, 
and stated that a small subset of 
cells within the overall tumor 
population were responsible for the 
initiation, propagation, and 
maintenance of the neoplasm (22). 
In order for this to be true, the CSC 
Figure 1. Symmetric and asymmetric division of stem cells. Stem 
cells (orange cells) are able to divide either asymmetrically into 
progenitor cells (pale blue cells), or into another stem cell through 
symmetric division. The symmetric divisions allow stem cells to 
continually repopulate the stem cell pool, whereas asymmetric 
division will give rise to progenitor cells. The progenitor cells then 
begin to differentiate in multipotent, early progenitor cells (pink cells) 
that will finally give rise to fully differentiated cell types (multi-colored 
cells) that make up the respective tissue.  
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population would need to display two characteristics that were already demonstrated by 
the somatic stem cell population, 1) self-renewal and 2) the ability to give rise to 
differentiated cell types (Figure 1) (9). By satisfying both of these requirements, CSCs 
would be able to maintain the necessary stem cell population, as well as produce the 
heterogeneous assortment of cells seen in malignancies.	 
 
     The belief in CSCs was bolstered when Dick and colleagues were able to isolate a 
CSC population within leukemia. Their work was the initial demonstration that a single 
malignant cell could be administered in vivo and result in the onset of leukemia. The 
induction of leukemia was capable of being carried out in serial experiments by isolating 
the CSCs, and re-injecting that population into subsequent animals. The very first CSC 
marker definition that they utilized was CD34+/CD38- (22).  
 
     Due to the impact of this finding, the cancer research community began to 
investigate the possible presence of CSCs in all other forms of cancer. Since that time, 
CSCs have been defined in multiple cancer types including breast, prostate, pancreas, 
brain, ovary, and colorectal (23-28). However, this population has yet to be exhaustively 
defined in NSCLC. 
 
Lung Cancer Stem Cells 
 
     In the search for lung CSCs, researchers have developed a set of criteria in order to 
delineate the stem cell population from that of the bulk tumor. The majority of these 
characteristics have been adopted from the traits that normal, somatic stem cells 
display. This approach has been utilized to define the CSC population throughout 
numerous cancer types, and is being adopted similarly in lung cancer (10). The required 
traits are commonly evaluated based on in vitro and in vivo assays, with the latter 
approach providing the most definitive demonstration of a CSC. These approaches and 
the traits they assess are briefly explained below. 
 
In vitro Cancer Stem Cell Assays 
 
     There are a number of popular in vitro studies being utilized to demonstrate the 
difference in the prominence of the CSC phenotype between various cell populations. 
These techniques include sphere formation, soft agar colony formation, collagen 
invasion, matrix degradation studies, and chemotherapeutic resistance assays (14, 29-
32). These assays demonstrate necessary characteristics of CSCs. Examples of this 
include the ability to grow in an anchorage independent manner. The ability to grown in 
the absence of a matrix is a hallmark of transformed cells. Spheroid formation and soft 
agar colony formation are both assays designed to evaluate a cells ability to proliferate 
in the absence of matrix attachment (33). Additionally, spheroid culture techniques 
utilizing restricted media formulations are often implemented to specifically enhance 
CSC populations. The reduction of differentiation-inducing factors allows for the 
expansion of the undifferentiated CSC population (34, 35).  
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     The ability of malignant cells to degrade matrix and invade into the surrounding 
tissue are two necessary processes of metastasis (36, 37). Interestingly the emergence 
of metastatic disease is associated with increased mortality, where 90% of cancer 
deaths are caused by metastases (38). The ability to establish metastatic disease has 
been connected to the CSC population (19, 39). Migration and invasion capabilities are 
often evaluated using a number of assays including wound healing, trans-well migration, 
spheroid invasion, and organotypic cultures that more closely resemble the in vivo 
environment (40, 41). Increases in these characteristics are often observed in the CSC 
population in comparison to the non-CSC population, demonstrating a more invasive 
phenotype (42). 
 
     Finally, examining the therapeutic resistance of a CSC population demonstrates the 
inherent trait of being unaffected by cytotoxic therapy. Malignant cells that are resistant 
to both chemotherapeutic and radiation treatments can lead to the recurrence of cancer 
following significant reduction of the disease due to bulk tumor susceptibility to these 
approaches (43). The resistance of CSCs to therapeutic approaches is so robust that 
often CSCs are often selected for by treatment with chemotherapeutic drugs or radiation 
(13). These results demonstrate the difficulty faced when trying to eliminate this 
population, and demonstrate that treatments spare CSCs in comparison to the overall 
tumor cell population (44).  
 
     In an effort to enhance the CSC population, and reduce the presence of non-CSCs, 
these described techniques tend to utilize cells that are cultured as spheroids. The 
ability to survive and expand in spheroid culture has been demonstrated to enhance the 
stem cell signature in both cancer and normal cells (45, 46). Thus, it makes utilizing 
spheroid culture an adequate method by which to expand the desired population for use 
in subsequent experimentation.  
 
In vivo Cancer Stem Cell Assays 
 
     A hallmark of a CSC population is increased tumorigenic propensity in comparison to 
bulk tumor populations. Demonstration of increased tumor initiating capabilities can be 
exhibited by injecting far fewer numbers of CSCs into immunocompromised animals, in 
comparison to heterogeneous cell populations. The results demonstrate that injections 
with reduced CSC numbers continually lead to tumor engraftment and growth that 
resemble results observed with utilizing significantly greater numbers of non-CSC (47). 
This is known as the in vivo limiting dilution assay, which continues to be held as the 
gold standard demonstration of a CSC population. Tumors that arise can then be 
assayed for resistance to therapy, invasiveness, and metastasis to sites such as the 
lymph nodes, liver, bone, and brain. (48-51).  
 
     Self-renewal of the CSC population is also evaluated in vivo by performing serial 
tumor forming assays in immunocompromised mice. Much like serial spheroid formation 
assays in vitro evaluate a population’s ability to continually replenish the CSC 
population, so do serial tumor forming assays (10). Continued tumor formation following 
dissociation of primary tumors and injection into secondary recipients demonstrates the 
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population’s ability to continually produce the tumor initiating, CSC population. Further 
serial injections are often performed to validate the self-renewal capabilities of the 
population in question (52).  
  
     The assays described above provide a functional validation of the CSC phenotype, 
however they do not provide a suitable definition of the population of cells of interest. In 
order to be able to effectively isolate and identify the CSC population it is commonplace 
to select cells based on markers, often cluster of differentiation (CD) markers are 
utilized. These markers are present on the surfaces of cells, and have been utilized to 
isolate cell types depending on their specific CD marker expression (53). In the search 
for CSCs, many investigators have coopted CD markers from other cancer types to 
investigate their potential as a useful identifier of CSCs within their cancer of interest. In 
addition to CD markers, the utilization of hyperactive signaling cascades can also be 
utilized to define a CSC population.  
      
     Currently, NSCLC research is at the stage of utilizing known CSC markers from 
other defined CSC populations like those found in breast, prostate, and glioblastoma in 
an effort to isolate the NSCLC CSC population. Below, we review the most commonly 
implemented markers and signaling pathways used in the attempt to define the NSCLC 
stem cell population. (Figure 2) It should be noted that this field is currently in its infancy, 
and there exist a large number of conflicting reports that make it very difficult to support 
the utilization of many of these CSC markers in NSCLC.  
 
Cluster Differentiation Markers 
 
CD133 
     CD133, also known as Prominin 1, 
is a five transmembrane glycoprotein 
initially believed to be a hematopoietic 
and neural stem cell marker in 
humans (54, 55). It has since been 
confirmed to be a hematopoietic stem 
cell marker, and is utilized in the 
screening of blood cells for allogenic 
transplantation (56). CD133 has also 
been employed to identify the stem 
cell population within various types of 
malignancies including colorectal, 
brain, gastric, and NSCLC (57-60). 
Cells that are determined to be 
CD133+ within a tumor have been 
reported to demonstrate the 
characteristics associated with CSCs 
and function as prognostic indicators 
(57, 61). While this CSC marker is 
believed to be highly correlative to the 
 Figure 2. CD markers and cellular detoxification in non-small 
cell lung cancer. Cancer stem cell populations are commonly 
separated based on CD markers or detoxification pathways. 
Common CD markers utilized in determining the non-small cell 
lung cancer population include CD133 and CD44. CD133, a five-
transmembrane receptor, currently has no known function. CD44, 
the hyaluronic acid receptor, has been utilized as a popular CSC 
marker in a number of malignancies. ABC pumps are responsible 
for the characterization of the side population. Cells that express 
the ABC transporters are capable of extruding Hoechst dye, and 
those cells with low dye retention are classified as the stem cell 
population. Aldehyde dehydrogenase enzyme activity has been 
utilized across many cancer types to define the CSC population. 
Cells with high aldehyde dehydrogenase activity, as defined by the 
Aldefluor Kit, have been demonstrated to have increased CSC 
characteristics compared to those with low aldehyde 
dehydrogenase activity.   
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CSC phenotype, there are a number of conflicting reports concerning its association 
with stemness. An example of this can be seen in the opposing findings produced by 
Tirino and Meng et al (5, 62).  
 
     Tirino and colleagues have shown CD133 to be a strong marker of stemness, 
selecting for cells with increased abilities to form spheres, increased levels of 
anchorage-independent colony formation, and increased tumorigenic potential in vivo. 
However, Meng and colleagues refute these findings by reporting that both CD133+ and 
CD133- tumor cells are capable of forming spheres, as well as give rise to colonies in 
soft agar experiments. Meng et al. also reported that CD133+ and CD133- cells were 
both capable of in vivo tumorigenesis, and conveyed no discernable difference in their 
invasiveness or resistance to chemotherapeutics. 
 
     While the studies referenced above demonstrate a difference in opinion, they are not 
the only ones to do so. A large amount of literature can be found either for or against 
the concept that CD133 expression can be utilized as a reliable marker to define the 
CSC population within a tumor (57, 63, 64). Currently, it is clear that more research 
must be done to determine if CD133 can be utilized as a definitive marker for CSC 
within a heterogeneous tumor population. 
 
CD44 
     CD44, like CD133 is an integral membrane glycoprotein expressed on the surface of 
cells, and functions as the hyaluronic acid (HA) receptor (65). CD44 is most well known 
for its role as a CSC marker in both breast and prostate cancers. CSC populations in 
these tumors are defined as CD44+/CD24-/low, and it is this population that is said to 
harbor the necessary traits to be defined as CSCs (23, 66). Currently, the usage of 
CD44 in lung cancer is not well studied. However, in accordance with implementing 
known CSC markers from other cancer types, researchers are beginning to explore the 
possibility of utilizing CD44 as a NSCLC stem cell marker. In one study, Leung and 
colleagues discovered that CD44+ NSCLC cells were enriched in stem cell properties, 
but this finding was only applicable to their large cell carcinoma model. The stem cell 
characteristics of CD44+ cells collected from an adenocarcinoma model failed to 
demonstrate the increased tumorigenecity or drug resistance, seen in the LCC model 
(67).   
 
     In agreement with the findings mentioned above, Wang et al. demonstrated that 
CD44+ cells collected from NSCLC also had increased stem cell properties, however 
this study also utilized the secondary marker, CD90, to further select the cell population 
of interest. It was observed that upon collection of CD44+ cells, the properties displayed 
by CSCs increased in this population. The phenotype was further enriched upon 
secondary selection with CD90 (68). The subsequent CD44+/CD90+ classification calls 
into question the value of CD44 as a standalone CSC marker in NSCLC. It is difficult to 
say that the population collected by CD44 alone is the stem cell population due to CD90 
increasing the CSC characteristics further. This study lacked the control of utilizing 
CD90 alone as a CSC marker. Recently, CD90 has been shown to define the CSC 
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population in esophageal cancer, further calling into question the applicability of CD44 
as a CSC marker in tumors that have yet to have a defined CSC population (69).  
 
     Overall, CD44 has functioned extremely well as a CSC marker for both prostrate and 
breast cancer. However, in NSCLC there is still little evidence to support the use of 
CD44 as a CSC marker. Undoubtedly the completion of future work will elucidate 




Aldehyde Dehydrogenase (ALDH) 
     Aldehyde dehydrogenases are a family of enzymes responsible for detoxification, 
drug resistance and cell differentiation. Their role in normal cellular metabolism is the 
oxidation of harmful aldehydes into carboxylic acids, and the conversion of retinol into 
retinoic acid (70, 71). Tumor cells that are positive for ALDH (ALDHhigh), and cells that 
are negative (ALDHlow) are often selected utilizing the Aldefluor kit from Stem Cell 
Technologies. This kit enables the labeling of cells with high levels of ALDH activity, and 
allows sorting utilizing fluorescence assisted cell sorting (FACS) analysis.  
 
     In the lung epithelia, the expression and induction of isoforms ALDH1A1 and 
ALDH3A1 have been thoroughly investigated. It has been shown that the expression of 
both isoforms increase during malignant transformation of normal lung tissue (72, 73). 
Other studies have also demonstrated an increased expression of ALDH1A1 and 
ALDH3A1 in NSCLC cell lines (74). Interestingly, it was also observed that the 
expression of ALDH is higher in the NSCLC than the expression detected in SCLC 
leading to the possibility that ALDH expression may be a specific marker for NSCLC 
CSCs (72).  
  
      These initial studies provided some support that the activity of ALDH isoforms may 
be involved in NSCLC tumor initiation, progression, and stem cell maintenance. In 
subsequent studies conducted by Sullivan and colleagues (75), it was found that 
NSCLC cells that were found to be ALDH1A1+ had increased tumorigenicity, 
clonogenicity, and self-renewal capabilities in comparison to ALDH1A1- controls. These 
findings were further supported by the correlation of poor clinical outcome in patients 
harboring ALDH+ tumors. Furthermore, this study demonstrated inhibition of the Notch 
signaling pathway greatly decreased the levels of ALDH+ cells, as well as their CSC 
characteristics.  
 
      In the Sullivan et al. studies discussed above, a controversial overlap between two 
purported CSC markers is highlighted. It has been suggested that one CSC marker, 
Notch, is responsible for the expression of another CSC marker, ALDH. In addition to 
the overlap, this study also disputed the previously discussed CSC marker CD133. In 
the manuscript by Sullivan and colleagues, CD133 did not correlate with poor patient 
prognosis, indicating that it may not function as reliable prognostic tool. Additionally, 
these results demonstrate that, in some instances, CSC markers believed to be 
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perpetuating the CSC phenotype on their own may be working in conjunction with other 
CSC markers.  
 
 Side Population 
     The side population of tumor cells, is defined as those cells that are capable of efflux 
of the Hoechst 33342 dye (76). The ability of cells to have a high efflux capacity has 
been demonstrated in cancer stem cell populations, thus it can be utilized as a marker 
for the CSC population (77). Stem cells, and CSCs alike are able to efflux the dye 
through an up regulation of the ATP-binding cassette (ABC) family of transporters (78). 
These proteins lie within the membrane of cells and are responsible for the export of 
endogenous entities, as well as the expulsion of cytotoxic compounds used to treat 
malignancies (17).  
 
     It has been demonstrated repeatedly that the SP is capable of increased colony 
formation, tumor sphere formation, invasion, and drug efflux (17, 20, 79-81). Taken 
together, these characteristics provide a strong basis for characterizing these cells as a 
CSC population. However, it has also been demonstrated that cells making up the non-
SP population are capable of giving rise to a SP. Additionally, the SP was also able to 
convert to other well-studied CSC such as CD133+ and ALDHhigh cells (82). Findings 
such as this make it difficult to state whether a single marker is sufficient for defining the 
CSC niche, or perhaps that these cells are able to transiently express certain markers 





     The Notch family of transmembrane receptors plays a critical role in determination of 
cell fate during development, as well as 
in the maintenance of the somatic stem 
cell population (83). Within the family, 
there are four Notch receptors (Notch1-
4) and five ligands (Delta-like-1, 3, 4 
and Jagged-1, 2) (84). Unlike normal 
receptor-ligand interactions the Notch 
ligands are not in a soluble form, but 
instead are present on neighboring cells 
as single transmembrane proteins (85). 
  
     Notch signaling begins with the 
binding of the Notch receptor to one of 
its ligands. Following binding, the 
extracellular domain of Notch is 
dissociated from the transmembrane 
domain and trans-endocytosed by the 
cell expressing the ligand. Upon 
removal of the extracellular domain, 
Figure 3. Notch signaling pathway. Notch signaling occurs 
between two neighboring cells where one expresses the Notch 
receptor, while the other expresses one of the Notch ligands, 
Delta or Jagged. Binding of the Notch receptor leads to a 
proteolytic cleavage by the ADAM family of metalloproteases 
and γ-secretase, releasing the notch intracellular domain 
(NICD). Free NICD then translocates to the nucleus where it can 
bind to the promoter of Notch effector genes such as Hes1 and 
Hey1. The Notch downstream effectors then go on to effect 
cellular differentiation and stemness. 
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there are two proteolytic cleavages of the transmembrane domain, 1) by ADAM10 or 
ADAM17 and 2) by γ-secretase. These two cleavage events release the Notch 
intracellular domain (NICD) liberating it to translocate to the nucleus and act to alter 
transcription (84) (Figure 3). There are a wide variety of transcriptional targets of the 
NICD, including those pertaining to differentiation and stem cell maintenance (86). 
Interestingly, it has also been shown that increased Notch signaling correlates with 
increased activity of ALDH, as well as an observation that CD133+ cells have enhanced 
Notch signaling (87, 88). The overlap of numerous stem cell promoting pathways 
observed within the mentioned populations provides evidence that the CSC population 
may rely on multiple mechanisms to sustain the population.  
 
     In addition to functioning as a possible regulator for ALDH+ and CD133+ cells, Notch 
signaling has been demonstrated to impart a CSC phenotype in cells on its own. In 
NSCLC, increased Notch signaling has been shown to enhance the CSC phenotype, 
and correlates with poor patient prognosis in comparison to patients with low levels of 
Notch signaling (89, 90). It has been observed that increases in Notch signaling 
increase tumorigenicity, chemotherapeutic resistance, and radiation resistance (89, 91). 
The combination of these qualities demonstrate that cells with increased Notch 
signaling are more resistant to therapies than populations with reduced Notch activity 
and therefore limit the efficacy of therapeutic intervention, leading to decreased survival 
in clinic (92, 93).  
 
      Attempts to lessen the levels of Notch signaling have been attempted in NSCLC, 
utilizing γ-secretase inhibitors (94). This approach hopes to lessen the numbers of CSC 
within the cancer population, and thereby increase the ability of chemotherapeutics and 
radiation to eradicate the non-CSC population and the overall tumor. Currently the use 
of Notch inhibitors in the clinic has made it as far as Phase I clinical trial, and inevitably 
more research will be done in order to advance the efficacy and safety of these drugs in 
the future years (85). 
	
Wnt Signaling 
     The Wnt pathway has long been known for its role in the regulation and maintenance 
of normal stem cells, such as those found in the gut epithelium (95). It has also been 
hypothesized that Wnt signaling can play a role in CSC regulation, where over-
activation of this pathway can lead to the emergence of the CSC phenotype (96). Wnt 
signaling is overviewed well by He et al, and will be briefly reviewed here (97). First, 
Wnt signaling functions through at least three known pathways within cells (98). The 
first, and best known, is the canonical pathway. Canonically, Wnt ligands bind to either 
the Frizzled or low-density lipoprotein receptor-related receptors present on the 
extracellular surface. This binding then activates Disheveled, a protein responsible for 
the inactivation of glycogen synthase kinase (GSK). Inhibition of GSK inhibits the 
phosphorylation of β-catenin, thereby stabilizing it. Stabilization of β-catenin allows for 
its translocation to the nucleus where it is able to affect gene transcription (Figure 4).  
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     Other, non-canonical Wnt 
signaling includes the planar cell 
polarity and Wnt/Ca2+ pathways (98, 
99). In addition the planar cell 
polarity pathway has also been 
demonstrated to lead to the 
activation of the small GTPases 
Rho, Rac, and Cdc42 (100-102). 
Interestingly, the Rac family of 
GTPases has also been implicated 
in the maintenance of the CSC 
population (79).  
 
     While the canonical Wnt/β-
catenin pathway has been shown to 
play a crucial role in the 
maintenance of CSCs in 
malignancies such as colon, liver, 
breast, and leukemia, its role in 
NSCLS has yet to be clarified (103-
106). Teng and colleagues were 
able to demonstrate that the 
canonical Wnt pathway was 
responsible for the maintenance of 
the CSC phenotype within A549 
cells by upregulation of OCT-4 and 
increasing levels of cyclin D1. It was discovered that this effect was caused by a 
decrease in the degradation of the basal level of β-catenin, hinting that the mechanism 
of action may effect the phosphorylation of free β-catenin (96).  
 
     The normal functions of the Wnt pathway and its downstream effectors are known to 
support and regulate the CSC population within tumors (107). Wnt signaling plays an 
important role in certain cancer types, but is still understudied as a potential mechanism 
of CSC maintenance in NSCLC. Future research will need to be conducted in order to 
confirm the utility of the Wnt/β-catenin pathway as a marker for the CSC population 
within NSCLC. 
 
Summary of CD Markers and Signaling Pathways 
 
     Overall, the results from studies investigating CSC markers and pathways tend to 
contradict one another in NSCLC. One study may find that a population positive for a 
certain CD marker will display a CSC phenotype while the population without the CD 
marker is still capable of demonstrating CSC characteristics in subsequent studies. 
When investigation switches from CD markers to known somatic stem cell signaling 
pathways, the results become clearer, however investigators often focus on upstream 




Figure 4. Wnt Signaling Pathway. 
The Wnt signaling pathway has been demonstrated to be important to 
the CSC population in a number of cancer types as well as in normal 
development. Under inactive conditions the Wnt effector protein, β-
catenin (β-Cat), is sequestered by the destruction complex and 
phosphorylated, thus targeting it for ubiquitination and proteosomal 
degradation. The destruction complex is composed of Axin, glycogen 
synthase kinase 3 (GSK3), adenomatosis polyposis coli (APC) and 
casein kinase 1 (CK1). During active signaling,  Wnt ligand binds to 
the LRP and Frizzled (Fz) receptors. Receptor activation causes the 
destruction complex to be recruited to the cytoplasmic tail of LRP by 
now phosphorylated Axin. Following relocation, Disheveled (DVL) is 
activated, thus inhibiting the action of GSK3. Loss of GSK3 activity 
leads to stabilization and accumulation of β-Cat within the cytosol. 
Accumulated β-Cat then translocates to the nucleus where it induces 
the transcription of Wnt target genes.  
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be Wnt signaling resulting in increased expression of the somatic stem cell marker Oct-
4 (96). These results cause us to wonder at which level of regulation is the effect being 
perpetuated. Inhibiting upstream regulators of these stem cell pathways can have 
numerous effects on all their downstream targets, therefore in order to create safe and 
effective therapies, it is important to understand and target the effector molecules that 
often lie further downstream.  
 
     Attempts to define the CSC population and target it have provided researchers new 
angles by which to attack cancer, however it is not CSC markers and pathways that 
have made up the bulk of drugs designed to target cancer. It is instead a myriad of 
pathways and proteins that are overexpressed or overactive in malignancies. The belief 
is that the reduction or inactivation of these pathways will result in decreased tumor 
aggressiveness and better patient outcomes. Common oncogenic drivers such as 
EGFR, K-Ras, and EML-ALK4 have all been shown to promote cancer initiation and 
progression, as well as become major foci of targeted therapies (108-110). Targeted 
therapy approaches often work well for a brief period of time, but over the course of a 
number of months these tumors become refractory to these therapies and the next line 
of therapy must be implemented. A great amount of research has been dedicated to 
understanding why cancer becomes resistant to these approaches and aims to design 
better drug formulations that may act in a more permanent fashion (111).  
 
     There also exists an interest in lesser-known, over-activated or over-expressed, 
proteins observed in cancers. These can include proteins that are important to certain 
cellular processes such as metabolism, cell motility, oxidative stress regulation, or 
autophagy (112-115). One of these proteins, NAD(P)H:quinone oxidoreductase 1 
(NQO1), has garnered a lot of attention recently as it is observed to be greatly over-
expressed in a number of cancer types, including NSCLC, but expressed at very low 
levels in normal tissues (116-118). This provides for an intriguing drug target as it can 
be a cancer directed therapeutic thus reducing unwanted off target affects. The role of 
NQO1 in cancer, and cancer therapy is discussed below.  
 
NAD(P)H:quinone oxidoreductase 1 
 
Overview 
     NAD(P)H:quinone oxidoreductase 1 (NQO1) is a phase II detoxifying that takes part 
in the obligate two electron reduction of harmful quinones, utilizing either NADH or 
NAD(P)H as a cofactor. The quinones present within the cell can arise from exogenous 
or endogenous sources including, estrogen derived quinones, dopamine derivatives, 
and antitumor quinones (119-122). Unlike cytochrome p450 enzymes, this reduction 
results in a stable hydroquinone that does not produce harmful reactive oxygen species 
due to the presence of a free electron (123, 124). The stable hydroquinone formed by 
NQO1 is later conjugated to glutathione and excreted from the cell. Interestingly, NQO1 
has been demonstrated to be greatly overexpressed in a number of tumor types in 
comparison to normal tissues (118, 125-127). These observations present researchers 
with the possibility of being able to specifically target tumor cells utilizing NQO1 as a 
drug target, thus sparing normal cells due to an inherent low expression of NQO1.  
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     NQO1-specific antitumor approaches are being investigated utilizing the ortho-
napthoquinone, β-lapachone (β-lap). Isolated from the lapacho tree, this compound has 
been used medicinally for centuries and has recently garnered respect in cancer 
therapy (128). β-lap’s mechanism of action is strictly dependent on the expression of 
NQO1. NQO1 catalyzes the formation of an unstable hydroquinone form of β-lap that 
spontaneously reverts back to the parent compound, thus resulting in the release of 
reactive oxygen species. The level of reactive oxygen species released is extremely 
high resulting in DNA damage, PARP1 hyper-activation, nucleotide depletion, and 
eventual cell death (129). Promising pre-clinical results have supported β-lap’s 
promotion to clinical trial. Known clinically as ARQ-501, or ARQ-761, β-lap has reached 
stage II clinical trials in prostate cancer, as well as a currently enrolling stage I trial for 
other solid malignancies (NCT01502800). In addition to stand-alone therapy with these 
compounds, research is also being conducted to investigate the synergistic effects of β-
lap with radiation (130). It has been observed that ionizing radiation induces expression 
of NQO1 leading to a synergistic effect when β-lap is administered following radiation 
(131, 132). Despite the promise observed with β-lap treatment, caution must be taken 




     Wild-type NQO1 protein is targetable via β-lap treatment, however two 
polymorphisms of NQO1 exist. The *2 polymorphism, a cysteine to threonine 
substitution at nucleotide position 609, results in a proline to serine substitution at 
position 187 in the amino acid sequence (133, 134). The result of this polymorphism is a 
highly unstable protein that has undetectable activity and is quickly degraded (135). 
This form of the polymorphism is predicted to occur in 5-20% of patients (136). 
Surprisingly, the presence of this polymorphism has been linked to the susceptibility of a 
number of diseases including cancer, as well as often predicting worse outcomes (137-
143). These results counter what is observed in other reports where wild-type NQO1 
expression leads to a worse overall survival, indicating a pro-tumorigenic role for NQO1 
(117, 144-146). The *3 polymorphism exists due to a cysteine to threonine substitution 
at nucleotide position 465 that results in an arginine to tryptophan substitution at amino 
acid position 139 (147). This polymorphism results in an alternative splicing event that 
renders substantially less protein in cells harboring the polymorphism (148). Studies 
investigating the prevalence of these polymorphisms demonstrate that the *3 




     Expression of the NQO1 gene is controlled by a number of factors including 
antiestrogens, electrophile response elements, and antioxidant response elements 
(ARE) (150-152). The most commonly discussed is its regulation by transcription factors 
binding to the ARE in the promoter region. The ARE consensus sequence, 
TMAnnRTGAYnnnGCRwww, is capable of binding a number of bZIP transcription 
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factors including Nrf1, Nrf2, Maf, 
Jun, Fos, and Raf (153). 
Additionally, it has been seen that 
ERK signaling can result in the 
increased expression of ARE 
regulated genes (154).  
 
     The canonical regulation of 
NQO1 is provided by the 
transcription factor NF-E2-related 
factor 2 (Nrf2) (153). Much like 
NQO1, Nrf2 is also a commonly 
studied protein in cancers as it too 
has been observed to have an 
increased expression in a number 
of cancer types (155, 156). Nrf2 
exists in equilibrium with its 
negative regulator Kelch-like ECH-
associated protein 1 (Keap1). 
Keap1 binds to Nrf2 and 
sequesters it in the cytoplasm, 
restricting the transcription factor 
from interacting with the DNA and inducing transcription. The binding of Keap1 to Nrf2 
allows for the Cullin 3 (Cul3)-based E3 ubiquitin ligase to associate with the complex, 
inducing the poly-ubiquitination of Nrf2 and subsequent proteosomal degradation (157). 
Under periods of oxidative stress, the Nrf2/Keap1 association is lost due to the oxidation 
of cysteine residues on Keap1 (158). Loss of association allows for Nrf2 accumulation 
and relocation to the nucleus. Upon localization to the nucleus, Nrf2 can bind to the 
AREs of its canonical targets and induce their expression (159). In addition, roughly 
15% of lung cancer patients harbor Keap1 mutations that inhibit the interaction of Keap1 
with Nrf2 that leads to increased activity of Nrf2 (156) (Figure 5). 
 
     Interestingly, Nrf2 has recently been demonstrated to regulate the expression of 
Notch and control the division and proliferation of normal bronchial stem cells (160). The 
report directly connects oxidative stress regulation to the maintenance of stem cell 
populations, and suggests that this may also be the case in the cancer stem cell 
population. Of note, it has also been demonstrated that increased Notch activity results 
in an increase in Nrf2 expression in liver cancer (161). These observations suggest that 
there is a reciprocal regulation of these two proteins by one another (162). 
 
Summary 
     Research into the role that NQO1 plays in promotion of tumorigenesis and why it 
tends to be overexpressed in a number of malignancies is essentially non-existent. The 
majority of research focus on tumor promotion is focused on the canonical NQO1 
regulator, Nrf2 and its tumor supportive role (163, 164). Given that there is little work 
focused on understanding the role of NQO1 in tumorigenesis, it comes as no surprise 
Figure 5. Nrf2 regulates the expression of NQO1 and other 
oxidative stress regulating genes. The expression of NQO1 is under 
the control of the Nrf2/Keap1 pathway. Under homeostatic conditions, 
Nrf2 is bound by Keap1 in a complex that includes the Cul3 ubiquitin 
ligase. Under these steady state conditions Cul3 is capable of 
polyubiquitinating (grey circles) Nrf2, thus targeting it for proteosomal 
degradation. Under conditions of oxidative stress, Keap1 acts as a 
sensor that then releases Nrf2. The free Nrf2 is then capable of 
translocating to the nucleus and binding to antioxidant response 
elements (ARE), along with other co-activators (Maf pictured) of 
oxidative stress regulating genes, including NQO1.  	
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that the importance of this oxidative stress regulator, in the CSC population, has also 
not been evaluated. Here we present work that demonstrates NQO1 plays a vital role in 
NSCLC initiation and progression, as well as being imperative in the maintenance of the 
CSC population in NSCLC. These results provide novel insight into the greater 
involvement of NQO1 in the promotion and progression of NSCLC, beyond its simple 
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     The fundamental role that NAD(P)H/quinone oxidoreductase 1 (NQO1) plays, in 
normal cells, as a cyto-protective enzyme guarding against stress induced by reactive 
oxygen species (ROS) is well documented. However, what is not known is whether the 
observed overexpression of NQO1 in neoplastic cells contributes to their survival. The 
current study discovered that depleting NQO1 expression in A549 and H292 lung 
adenocarcinoma cells caused an increase in ROS formation, inhibited anchorage-
independent growth, increased anoikis sensitization and decreased 3-D tumor-spheroid 
invasion. These in vivo data further implicate tumor-NQO1 expression in a pro-tumor 
survival role, since its depletion suppressed cell proliferation and decreased lung tumor 
xenograft growth. Finally, these data reveal an exploitable link between tumor-NQO1 
expression and the survival of lung tumors since NQO1 depletion significantly 




      
     Lung cancer is the leading cause of cancer related deaths in the U.S. (2). Over the 
past decade some improvement has been made toward the goal of increasing overall 
survival in lung cancer patients. These improvements have mostly been due to 
technological advances allowing early diagnosis of lung cancer as well as improved 
molecular based therapeutic approaches (165). However, with 5-year survival rates at 
15% or less, novel mechanism based therapeutic approaches are still desperately 
needed.  
 
     NADPH quinone oxidoreductase-1 (NQO1) is an inducible two-electron 
oxidoreductase that is highly overexpressed in many solid tumors including breast, 
pancreas and non-small cell lung cancer (NSCLC) (116, 118, 166-171). NQO1 is an 
essential phase II detoxification gene and as such plays a critical role in both 
detoxification and bio-activation of many DNA damaging quinones (167). As a chemo-
preventive gene, NQO1 has been shown to detoxify a broad spectrum of quinone 
substrates and it plays a role in reactive oxygen species (ROS) scavenging by 
generating antioxidant forms of alpha tocopherol (167, 172).  
 
     In our past investigations we demonstrated that NQO1 bioactivated several 
anticancer quinones including b-lapachone (173) and more recently deoxynyboquinone 
(DNQ) (174). Our previous in vitro studies determined that NQO1 is a viable target for 
developing personalized lung cancer therapy since tumor-NQO1 levels are often 5-20 
fold greater in lung tumors as compared to the levels of NQO1 observed in associated 
normal tissues (170). Thus, targeting NQO1 with anticancer quinones has become a 
feasible option for preclinical anticancer studies. Furthermore, our in vivo studies with 
anticancer quinones and novel drug delivery formulations, has led to a surge in interest 
in NQO1-bioactivated anticancer quinones (174, 175), resulting in clinical trials for 
treatment of various solid tumors. However, there is still very little known as to why 
NQO1 levels are so vastly overexpressed in solid tumors. More specifically, no studies 
have addressed whether reducing tumor-NQO1 levels affects processes critical to 
tumor survival and proliferation, including anchorage-independent growth, escape from 
apoptosis and the ability to invade and metastasize. 
 
      In the current study we hypothesized that depleting NQO1 expression levels in 
NSCLC tumors would have deleterious effects on cell proliferation and survival. Our 
rationale for this hypothesis stemmed from numerous reports suggesting that cancer 
cells must regulate oxidative stress levels to prevent death from toxic levels of ROS 
created in their microenvironment as part of a host defense response (176). Thus, one 
strategy to protect tumor cells from lethal levels of ROS stress is to activate, or hijack, 
pathways that regulate the expression levels of antioxidant genes. Importantly, a 
primary regulator of oxidative stress is the transcription factor Nrf2 whose role is to 
activate antioxidant gene expression; and its own overexpression has been associated 
with enhanced tumorigenesis (163, 177, 178). One of the many transcriptionally 
activated antioxidant genes regulated by Nrf2 is NQO1, and numerous studies have 
shown that NQO1 levels in various tumors are elevated in comparison to associated 
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normal tissues (116, 118, 170). Here we show that depletion of NQO1 expression 
levels, in various NSCLC cell lines, decreased the tumor cells ability to form colonies in 
anchorage-independent growth assays. The inability of NQO1-depleted NSCLC cells to 
form tumor colonies in anchorage-independent assays correlated with increased 
reactive oxygen species formation, an increase in anoikis sensitization and a decrease 
in cell proliferation rates. Our data also show that depletion of NQO1 expression levels 
inhibited the ability of NSCLC cells to invade in 3D-tumor spheroid assays. Our in vivo 
data show that loss of tumor-NQO1 expression in NSCLC cells inhibited tumor growth 
as compared to controls. Finally, we show that NQO1 knockdown decreases the 
percentage of ALDH(high) cancer cells, suggesting that the depletion of NQO1 decreases 
tumorigenicity by eliminating the cancer stem cell population within the tumor. Together 
these novel findings illuminate the role of NQO1 in tumors, and suggest that depleting 
tumor-NQO1 levels disrupts the protective barrier against ROS provided to cancer cells 
by elevated tumor-NQO1 expression levels. Thus, NQO1 depleted tumor cells are more 
susceptible to oxidative stress and their overall growth and survival is inhibited due to 
increased cell death, and reduced proliferation of the cancer stem cell population. 
 
Materials and Methods 
 
Reagents 
     NQO1 activity assay kit (Abcam), Cell death detection ELISA kit (Roche Applied 
Sciences), Seaplaque agarose, SeaKem agarose, 1N Sodium Hydroxide and Rat tail 
collagen type I (Fisher Scientific), Noble agar (Becton, Dickinson), 10X DPBS 
(Hyclone), Cyquant cell proliferation assay kit and 2', 7'-dichlorodihydrofluorescein 
diacetate, acetyl ester, DCFDA (Lifetechnologies). The NQO1 inhibitor Mac220 was a 
generous gift from Dr. David Ross, University of Colorado Anschutz Medical Center. 
 
Cell growth and maintenance assays 
     H292, HCC1171 and non-transformed, non-tumorigenic human bronchial epithelial 
(HBEC) cell lines were a generous gift from the laboratory of Dr. John D. Minna, UTSW 
Medical Center at Dallas. A549 and H596 cells were previously described (170). A549, 
H596, H292 and HCC1171 cell lines were cultured in DMEM (Lonza) containing 10% 
fetal bovine serum (FBS) and 1% L-glutamine. HBEC cells were cultured in 
Keratinocyte Serum-Free Media with supplements (Invitrogen). All cell lines were 
incubated at 37°C at 10% CO2. 
 
Western Blotting 
     Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF 
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room 
temperature, and then incubated overnight with β-actin (1:5000 in 3% BSA, Santa Cruz 
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with 
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was 
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa 
Cruz Biotechnology). Pierce ECL western blotting substrate (Thermo Scientific) was 
used to visual bands on Hyblot-CL autoradiography film (Denville Scientific).  For 
PARP-1 cleavage assays, A549 (shCtr-R and shNQO1) tumors were harvested post 
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mortem and sonicated in PARP-lysis buffer as described previously (173, 179). Extracts 
were resolved in 10% SDS-PAGE gels and transferred to a PVDF membrane. PARP-1 
protein was visualized using a monoclonal PARP-1 antibody (Santa-Cruz, clone F-2) at 
a 1:1000 dilution. 
 
Patient survival analysis 
     Three separate survival analyses were performed on overall survival data from 
NSCLC patients obtained from 3 TCGA data sets (https://tcga-data.nci.nih.gov/tcga/) 
(180-182). Gene expression values used were reported from Affymetrix U133A 
Microarray data. Patient data with valid gene expression levels were used to estimate 
medians and bounds for upper and lower quartiles. Patients were categorized into two 
groups based on whether the values of gene expression were above the upper quartile 
bound and below the lower quartile bound. Kaplan–Meier survival graphs were plotted, 
and log-rank tests were performed using GraphPad Prism.  
 
Transient and stable NQO1 protein knockdown assays   
     The human shRNA-NQO1 retroviral vector (RHS1764-9691437) was purchased 
from Open Biosystems. A stable shRNA knockdown cell line (A549-shNQO1) and 
vector control (A549-shCtr-R) was generated by infecting A549 cells with polybrene-
supplemented medium obtained from Phoenix packaging cells transfected with the 
human retrovirus vector targeting NQO1 or non-silencing control vector as described 
previously (168). Human shRNA-NQO1 lentiviral particles (sc-37139) and controls were 
purchased from Santa Cruz Biotechnology. Stable shNQO1 lentiviral knockdown (A549-
shNQO1-B) and control (A549-shCtr-L) lines were generated by infecting A549 cells 
with polybrene-containing culture medium (5 µg/mL) and 10 µL of the lentiviral particles 
were added directly to the culture medium. Medium was changed 24 hours after 
transfection. After 48 hours shNQO1 containing cells were isolated by limited dilution in 
media containing puromycin (2 µg/mL) and screened for NQO1 expression levels by 
Western blot. Similar experiments were performed with H292 cell lines to create H292-
shNQO1-B and H292-shCtr-L cell lines. H596 cells, which are NQO1 null, were infected 
with retrovirus particles from a retroviral control (LPC-X) or retroviral NQO1 (LPC-
NQO1) vector as described previously (9). For transient NQO1 knockdown, siRNA-
NQO1 or scramble control siRNA (Santa Cruz Biotechnology) was transiently 
transfected into HCC1171 or H596 cell lines (Lipofectamine 2000, Life Technologies) 
using the Life Technologies protocol. Cells were harvested after 48 hours and analyzed 
for NQO1 protein expression or enumerated using a hemocytometer for use in invasion 
assays.  
 
NQO1 activity assays 
     To analyze endogenous NQO1 levels we used an NQO1 activity assay kit (Abcam). 
Briefly, cell pellets, containing 2X107 cells, were collected for each cell line. Pellets were 
solubilized in 1X extraction buffer on ice for 20 minutes. Samples were then centrifuged 
at 18,000 x g for 20 minutes at 4°C. Supernatants were transferred to new eppendorf 
tubes and aliquots were stored at -80°C. Protein concentration was determined using 
the Bio-Rad protein assay method. Samples were diluted to 2X the working 
concentration of 5 µg/mL with supplemented buffer. Two wells were prepared for each 
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sample (one well with and one well without inhibitor). 50 µL of each cell line was plated 
in triplicate in 96 well plates provided with the kit. The reaction buffer and the reaction 
buffer plus inhibitor were prepared according to the manufacturer’s calculation table. 
The reaction buffer plus inhibitor were added to the samples first. Reaction buffer 
without the inhibitor were added last. Absorbance was measured at 440 nm every 20 
seconds for 5 minutes using the Synergy-H1 Hybrid microplate reader. The plates were 
shaken before and after each reading.   
 
In vitro survival assays 
     Long-term survival assays based on DNA content after 7-10 days of growth were 
conducted in 48 well dishes as previously described (170, 173). Cells were treated with 
vary doses of ARQ-761 (aka b-Lapachone) in the presence or absence of the NQO1 
inhibitors dicoumarol or 5 µM Mac 220.  
 
Cell Proliferation Assays 
     To determine cell proliferation rates we used the CyQUANT cell proliferation assay 
kit (Life Technologies) and followed the manufacturers protocol. Briefly, standard curves 
were generated by pelleting 1X106 cells for all cell lines. Pellets were resuspended in 1 
mL of CyQUANT GR/cell-lysis buffer and vortexed briefly. A dilution series in one row of 
a 96 well microplate ranging from 50 to 50,000 cells per cell line in total volumes of 200 
µL were plated along with a 200 µL control well with no cells and incubated for 5 
minutes in the dark at room temperature. Using a Synergy-H1 Hybrid Reader (Bio Tek), 
fluorescence was measured at excitation 480nm and at 520nm emission. For 
proliferation, cells were plated out in 6 wells at 5,000 cells per well in a total of 200 µL of 
a 96 well plate. Multiple plates were seeded using the same starting concentration and 
cultured at 37°C and 10% CO2 until desired time to collect the plates. Plates were 
collected at 0, 24, 48, and 72 hours by inverting the plates and blotting on a paper towel 
to remove medium from the wells. Plates were stored at -80°C until all plates were 
collected. Plates were thawed at room temperature and 200 µL of CyQUANT GR/cell-
lysis buffer was added. Plates were incubated for 5 minutes in the dark at room 
temperature. 
 
Anchorage-independent growth assays 
      For A549 cell lines, a 1.5% SeaPlaque Agarose (SPA) mixture was made by slowly 
adding SPA to PBS and autoclaving. 0.5% SPA was created by diluting the 1.5% stock 
SPA 1:3 with culture media. 1 mL of the 0.5% SPA mixture was added to each well of a 
6 well plate to create a bottom layer and allowed to solidify at room temperature for 15-
20 minutes. Cells were counted and suspended at 750 cells/mL in a separate 0.5% SPA 
mixture. 2 mL were added to each well on top of the bottom layer and allowed to solidify 
for 30-45 minutes at room temperature to create a cell layer. A 0.3% SPA mixture was 
created by diluting the 1.5 % stock SPA 1:5 with culture media. 1 mL of the 0.3% SPA 
mixture was added to each cell layer and allowed to solidify for 20-30 minutes at room 
temperature to create a top layer. 250-500 µL of culture media was added onto the top 
layer to prevent from drying out. A similar method was used where SeaKem Agarose 
was substituted for SeaPlaque Agarose yielding similar results. Plates were wrapped in 
parafilm and placed at 37°C. 250-500 µL of new culture media was added every week. 
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Plates were imaged after 3 weeks (A549 cells) and 6 weeks (H292 cells) using and 
Epson V700 photo scanner. The enumeration of colonies present in each dish was 
quantified using imageJ software.   
 
Cell Death Elisa (CDE, anoikis) assays 
     A cell death detection ELISA kit was used to determine the level of detachment 
induced cell death (anoikis). Briefly, cells were seeded at a density of 250,000 cells in a 
10cm dish for 48 hours prior to plating for assay. 2.0 mL of 0.5% methylcellulose and 
culture medium mixture was added to poly-HEMA coated plates and allowed to 
equilibrate in the incubator for 1 hour at 37°C. 150,000 cells were seeded per well in the 
0.5% methylcellulose mixture and incubated at 37°C for the 24 and 48 hour time points. 
For the zero hour time point cells were placed directly into Eppendorf tubes and placed 
on ice. Cells were lysed with 100 µL of CDE lysis buffer at 4°C for 20 minutes. Cells 
were pelleted for 12 minutes at 4°C at 13,000 rpm. 75 µL of the supernatant was 
transferred to a new tube and stored at -80°C until all time points were collected. All 
samples were processed using the cell death detection ELISA kit with the manufactures 
protocol. Absorbance values were recorded using the Synergy-H1 Hybrid reader (Bio 
Tek) at 405 nm. Values were calculated by subtracting the zero hour time point from the 
24 and 48 hours time points. 
 
Invasion assays 
     Invasion assays were performed as described previously (183). Briefly a 1.5% noble 
agar/ PBS mixture was made and then autoclaved. Using a multi-channel pipette, 100 
µL of the noble agar mixture was added to each well of a 96 well plate. Cells were 
counted and suspended at a density of 50,000 cells/mL. 200 µL of this suspension was 
added to the 96 well plates once the noble agar was solidified. Plates were allowed to 
sit for 1-3 days depending on cell line until spheroids were formed. Once spheroids 
were formed, a 400 µL base layer mixture of 10X DPBS, 1N sodium hydroxide, sterile 
water and rat tail collagen was added to a 24 well plate and allowed to solidify at 37°C 
for 30 minutes. Using a nucleofector pipette, spheroids were added one at a time to 
Eppendorf tubes. 3 spheroids were added to each tube. Spheroids were centrifuged at 
1,000 rpm for 3 minutes. The media was removed from each tube using a nucleofector 
pipette. A collagen cell layer mixture was made and 500 µL were carefully added to 
each tube, one at a time, and spheroids were added to the 24 well plates. The cell layer 
was incubated at 37°C for 1 hour. 1 mL of culture media was added to the top of the cell 
layer to prevent the collagen from drying out. Once media was added, zero hour images 
were taken at 5X (A549 and HCC1171 cells) or 10X (H292) magnification using an 
inverted microscope (Axiovert 200M, Zeiss). Images were taken every 24 hours until 
invasion distance was outside of the focal field of view. The scale bar in each image 
represents 100 microns. Using the AxioVision software, the invasion distance was 
calculated by subtracting the initial spheroid radius from the invasive distance at the 
final time point. 
 
DCFDA staining for ROS studies 
     500,000 cells were plated in 10 cm dishes containing 7 mL of 0.5% Methylcellulose 
mixture. Cells were incubated for 24 hours at 37°C and 10% CO2. After 24 hours pellets 
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were collect by centrifuging at 1,000 rpm for 2 minutes. Pellets were washed 1X with 
PBS and centrifuged at 1,000 rpm for 2 minutes. Pellets were resuspended in DMEM/F-
12 without phenol red, which contained either 5µM DCFDA (stained) or DMSO 
(unstained control), and transferred to flow cytometry tubes. Cells were incubated at 
37°C and 10% CO2 for 30 minutes. Cells were then pelleted again at 1,000 rpm for 2 
minutes. Pellets were resuspended in 500 µL of DMEM/F-12 without phenol red and 
placed at 37°C and 10% CO2 for 15 minutes to equilibrate and then samples were read 
using the LSR Fortessa (BD Biosciences). 
 
In vivo tumorigenesis and survival assays 
     For tumorigenesis assays 4-6 week old female athymic nude mice (Charles River) 
were subcutaneously injected on the right flank with A549 shCtr-R and A549 shNQO1 
cells on the left flank. Mice were stratified into 3 groups containing initial tumor injection 
concentrations of 5 million, 2.5 million or 1 million cells of each cell type. 10 mice were 
used for each group. Tumor growth rates were monitored by caliper measurements 
using the formula (L x W2/2). Statistical significance between A549-shNQO1 and A549-
shCtr-R tumor growth rates, at each concentration, was calculated using an unpaired, 
two tailed Students t-test. 
 
     In separate studies, to compare the effect that NQO1 depletion had on overall 
survival, 4-6 week old athymic female nude mice (Charles River) were subcutaneously 
injected with A549-shCtr-R or A549-shNQO1 cells into their flanks. Tumor growth rates 
were monitored by caliper measurements using the formula (L x W2/2). Tumor growth 
was assessed until the tumors reached the set volume of 1000 mm3. Post mortem, 
tumors were collected for evaluation of NQO1 expression. Log-rank test were applied to 
survival analyses (Kaplan-Meir). All statistical significance assessments were conducted 
using Graph-Pad Prism 6 software. 
 
     All animal studies were performed in accordance with the animal care policies of 
West Virginia University and were approved by the West Virginia Animal Care and Use 
Committee. 
 
Aldefluor activity assays 
The percentage of cells that were ALDH(high) within the various cell populations assayed 
was determined using the Aldefluor Kit (Stemcell Technologies). The kit was used 
according to the manufactures protocol. Briefly, two flow cytometry tubes, per cell line, 
were labeled as control or test. Cells were trypsinized and pelleted at 1,000 rpm for 1-2 
minutes. 1 X 106 cells were then counted out for both shCtr-R and shNQO1 cell lines. 
Pellets were washed 1X with PBS and resuspended in 1mL of the Aldefluor Assay 
Buffer provided and transferred to the “test” tube. 5µL of the DEAB (ALDH inhibitor) was 
added to the “control” tube and was immediately recapped. 5µL of the Aldefluor reagent 
was added to the “test” tube and was vortexed immediately. After the “test” tube had 
been vortexed, 500µL of the Aldefluor Assay Buffer was transferred from the “test” tube 
to the “control” tube and the “control” tube was immediately vortexed. That procedure 
was repeated for each cell line. Once all cells line were stained, the “test” and “control” 
tubes were incubated at 37°C for 30 minutes. After the incubation period, tubes were 
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centrifuged at 250 rpm for 5 minutes. Supernatant was removed and pellets were 
resuspended in 500µL of Aldefluor Assay Buffer and samples were placed on ice. A549 
samples were assessed using a Fortessa flow cytometer and Mia PaCa and PC3 cell 
lines were analyzed using a Facs Calibur flow cytometer (Becton Dickinson). Final data 
analysis was performed using FCS Express software. 
 
Cell viability assays 
     HBECs were transiently transfected with siRNA-NQO1 or scramble control according 
to the protocol described above. After the 48 h transfection period, cells were 
enumerated and seeded at a density of 20,000 cells/ well in 96 well plates (white). The 
following day, the viability of cells in each group (8 wells/ group was assessed by adding 
100 µL of CellTiter-Glo (promega) to each well. Luminescence was detected using a 
Synergy-H1 Hybrid reader (Bio Tek).   
 
Statistical analysis 
     Statistical differences were determined by using Student's t tests, and p values were 
reported. All statistical analyses were 
performed using Graph-Pad Prism 6 
software, and considered significant 




Elevated NQO1 expression predicts 
poor survival in NSCLC patients.  
     In previous studies our laboratory, 
as well as other investigators, reported 
that NQO1 expression levels were 
highly elevated in lung cancer patient 
tumor versus associated normal lung 
tissue (170, 184). Elevated tumor-
NQO1 levels have provided a distinct 
advantage for developing NQO1-
directed anticancer therapeutics such 
as b-lapachone and deoxyniboquinone 
(174, 175). However, in more recent 
retrospective investigations of patient 
outcomes, a strong correlation 
between elevated tumor-NQO1 
expression levels and poor patient 
survival in various cancer types 
including breast and ovarian cancers 
has emerged (185, 186). Thus, we 
sought to determine whether elevated 
NQO1 expression in lung tumors also 
confers a survival disadvantage in lung 
 Figure 1. Elevated NQO1 levels in NSCLC patient tumors 
decreases their overall survival. In A, Kaplan-Meier analysis of 
patient survival based on tumor NQO1 expression levels from a 
TCGA data set. Patients were grouped into NQO1 low and NQO1 
high expression groups as described in “Materials and Methods”. 
In B, Western blot analysis of A549 and H292 cells stably 
transduced with retroviral (shNQO1) or lentiviral (shNQO1-B) 
NQO1 constructs. In C and D, A549 and H292 NQO1 knockdown 
cell models from (B) were assayed for NQO1 enzyme activity, and 
activity was expressed as nMoles/min/µg of protein. In C, p values 
for A549 shCtr-R vs A549 shNQO1  (p <0.0001) and for A549 
shCtr-L vs A549 shNQO1-B. (p = 0.0002)  In D, p values for H292 
shCtr-L vs shNQO1-B (p = 0.0114). 
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cancer patients. We analyzed gene expression and survival data from NSCLC (lung 
adeno- and squamous cell carcinoma) patients within The Cancer Genome Atlas 
(TCGA) (180-182). Patients were stratified into high and low NQO1 expressers based 
on a quartile bound cutoff. With this cutoff, a total of 191 patients were identified as high 
expressers and 244 patients were identified as low expressers. Our data, in three 
separate analyses, show that lung cancer patients with high tumor-NQO1 expression 
levels have worse overall survival (Figure 1A and Supplemental Figure 1). Our data 
are consistent with the aforementioned reports of poor overall survival in breast and 
ovarian cancer patients whose tumors had high NQO1 expression levels (185, 186). 
These data, as well as our laboratory observations that NQO1 levels increase during 
the process of transformation, suggested that cancer cells increase NQO1 expression 
levels as part of a pro-survival strategy during tumorigenesis, and that depleting NQO1 
levels could possibly eliminate this survival advantage. 
 
Depleting tumor-NQO1 levels inhibits anchorage-independent growth and 
invasion of NSCLC. 
     To investigate whether depleting NQO1 would alter the growth of lung cancer cells 
we used NQO1 shRNAs to establish stable 
knockdown of NQO1 in A549 and H292 
NSCLC cell lines. Our data show that 
shNQO1 knockdown in A549 cell lines 
using a retroviral vector (shNQO1) or 
lentiviral vector (shNQO1-B) caused a 
significant decrease in NQO1 protein 
expression levels (Figure 1B and 
Supplemental Figure 2A), which 
correlated with loss of NQO1 activity 
(Figure 1C). Similar results are shown for 
NQO1 knockdown in H292 cells (Figures 
1B lower panel and 1D). The parental 
A549 cells have nearly 12 fold higher levels 
of NQO1 activity as compared to the levels 
of NQO1 activity detected in H292 cells. 
Thus, these two cell lines with their distinct 
differences in NQO1 activity levels, also 
serve as an internal comparison to 
determine whether patients with lower 
NQO1 levels in their tumors could also 
benefit from therapeutic strategies aimed at 
depleting NQO1 expression.  
 
     A hallmark of oncogenic transformation 
is the newly acquired ability of a 
transformed cell to grow in an anchorage-
independent environment. This acquired 
phenotype also increases the invasive and 
 
 
Figure 2.  Depleting NQO1 expression levels inhibits 
growth of NSCLC cells in soft agar. In A, A549 shCtr-R 
and A549 shNQO1 cells were analyzed for their ability to 
form colonies and grow in soft agar. Photomicrographs 
shown are representative of experiments performed in 
sextuplet. In B- D, graphical representation of enumerated 
colonies for A549 shNQO1, A549 shNQO1-B and H292 
shNQO1-B cells versus A549 shCtr-R, A549 shCtr-L and 
H292 shCtr-L cells. In B, p values for A549 shNQO1 vs 
A549 shCtr-R (p (<0.0001). In C, p values for A549 
shNQO1-B vs A549 shCtr-L (p = 0.0041). In D, p values for 
H292 shNQO1-B vs H292 shCtr-L (p=0.0114). 
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metastatic potential of transformed cells. In previous reports A549 and H292 cell lines 
served as metastatic models for in vivo studies (187, 188). Thus, we hypothesized that 
stable shRNA knockdown of NQO1 in A549 and H292 cells would be sufficient to 
determine whether NQO1 depletion affected tumor growth in anchorage-independent 
colony forming assays (also referred to as soft agar assays). In Figures 2A-D and 
Supplemental Figure 3 our data show that stable depletion of NQO1 significantly 
inhibits the growth of A549 and H292 cells in soft agar assays. Interestingly, the 
inhibition of NQO1 expression in A549 cells using the shNQO1 vector was substantially 
greater than what was observed with 
the shNQO1-B vector. Thus, the higher 
NQO1 activity observed in shNQO1-B 
A549 knockdown cells (Figure 1 C) 
correlated with more colony growth 
(Figure 2C and Supplemental Figure 
2B). These data suggest that the 
degree of NQO1 activity loss affects the 
ability of cells to grow in soft agar. In 
addition to NQO1 shRNA knockdown 
studies we examined the effect of 
dicoumarol and Mac 220, NQO1 
inhibitors that mimic the co-factor 
NAD(P)H which is required for NQO1 
activity (189), on colony growth. Our 
data show that the NQO1 inhibitors 
dicoumarol and Mac220 also 
significantly inhibited the growth of 
A549 cells in soft agar colony forming 
assays (Supplemental Figures 4 and 
5), further confirming that anchorage-
independent growth in these cells is 
affected by the loss of NQO1 activity. 
 
     To further confirm the role of NQO1 
in anchorage-independent growth we 
examined the effect of NQO1 
overexpression in H596 cells, which are 
NQO1 null due to the *2 polymorphism. 
Our data show that NQO1 
overexpression in H596 cells (H596-LPC-NQO1) caused significantly more colony 
growth as compared to vector only H596-LPCX cells (Supplemental Figure 6). In 
contrast, our data show that transient knock down of NQO1 in H596-LPC-NQO1 cells 
results in significant loss in their ability to grow in soft agar (Supplemental Figure 7). 
These data further indicate that NQO1 plays a role in the survival of cells in an 
anchorage-independent environment.   
 
Figure 3.  Loss of NQO1 expression inhibits invasion of 
NSCLC. In A, and C, 3D- tumor-spheroid invasion assays were 
performed on A549 shNQO1, H292 shNQO1-B and A549 and 
H292 shCtr-L cell lines as described in “Materials and Methods”. 
Shown are photomicrographs of representative spheroids from 
each cell line at 0 and 72 (h). In B and D, graphical presentation 
of the tumor-spheroid invasion distance migrated by A549 
shNQO1 and H292 shNQO1-B cells as compared to A549 and 
H292 shCtr-L cell lines.  In B, p values for A549 shNQO1 vs 
A549 shCtr-R (p<0.0001). In D, p values for H292 shNQO1 vs 
H292 shCtr-L (p<0.0001)   
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     The ability to survive in an anchorage-independent environment is uniquely tethered 
to a cancer cells ability to invade and metastasize (190). Thus, we employed an in vitro 
3- dimensional spheroid invasion assay (183, 191) to address the role that NQO1 plays 
in the process of tumor cell invasion. Our data show that stable knock down of NQO1 in 
A549 cells decreased the overall area of lung tumor spheroids (Supplemental Figure 
8A) and inhibited the invasive progression of lung tumor spheroids in A549 and H292 
cells (Figures 3 A-D and Supplemental Figure 8B). In addition to A549 and H292 
cells, our data show that transient 
depletion of NQO1 expression using 
siRNA also inhibited invasion in 
HCC1171 lung cancer cells 
(Supplemental Figure 9). In 
contrast to NQO1 knockdown 
studies, when NQO1 was 
overexpressed in H596 cells a 
significant increase in invasion was 
observed (Supplemental Figure 
10).  Together these data 
demonstrate that NQO1 levels are 
critical for anchorage-independent 
growth and the invasion of lung 
cancer cells.  
 
NQO1 depletion elevates ROS 
levels and sensitizes cells to 
anoikis. 
     Previous investigations have 
shown that NQO1 can act as a 
scavenger of ROS (192), thus we 
hypothesized that depleting NQO1 
in our lung cancer models would 
increase endogenous levels of ROS. 
As expected, our data show that 
depletion of NQO1 in A549 cells 
caused an increase in oxidative 
stress as indicated by the increased 
DCFDA staining (a general ROS 
indicator including H2O2 levels 
(Figures 4 A-B), supporting our 
hypothesis that endogenous ROS 
levels are increased in lung cancer cells when tumor-NQO1 levels are depleted. 
 
     In transformed cells the intracellular production of ROS is tightly regulated to prevent 
programmed cell death (193). Excessive ROS production can lead to apoptotic 
catastrophe, and cells that escape apoptosis are resistant to detachment induced cell 
death, also known as anoikis (194). Anoikis resistant cells are capable of continued 
 
Figure 4. Depleting tumor-NQO1 levels increases ROS formation 
and sensitizes NSCLC to anoikis. In A and B, A549 shCtr-R, A549 
shNQO1, H292 shCtr-L and H292 shNQO1-B cell lines were stained 
with 5 µM DCFDA (Life technologies) to detect endogenous ROS 
levels (H2O2). In C and D cell death ELISA assays (Roche Applied 
Sciences) were performed on A549 and H292 NQO1 knockdown and 
control cells as described in “Methods” to detect cells that had 
undergone detachment induced cell death (anoikis). In A, p values for 
shCtr-R vs A549 shNQO1 (p = 0.004). In B, p values for shCtr-L vs 
H292 shNQO1-B (p = 0.0012). In C, p values for A549 shCtr-R vs 
A549 shNQO1 (p < 0.0001). In D, p values for H292 shCtr-L vs H292 
shNQO1 (p = 0.0001).	
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proliferation and distant tumor formation (195). Thus far, our data show that depleting 
NQO1 prevents anchorage-independent growth and increases ROS stress levels. 
Therefore, we further hypothesized that the inability of NQO1 depleted cells to grow in 
an anchorage-independent environment was linked to anoikis sensitization caused by 
increased levels of ROS. To test this hypothesis we performed cell death ELISA assays 
on NQO1 knockdown cell models. Our cell death assays show that loss of NQO1 in 
A549 and H292 cells significantly increased sensitization to anoikis (Figures 4C-D). 
These data suggest that depletion of NQO1 expression in lung cancer cells increases 
oxidative stress and potentiates 
detachment induced cell death. 
 
Depleting tumor-NQO1 
expression levels decreases 
cell proliferation and in vivo 
tumor growth. 
     Uncontrolled proliferation is 
a hallmark of malignant 
neoplastic cells, thus novel 
approaches to reduce 
uncontrolled cell proliferation 
are of paramount importance in 
the development of anticancer 
strategies. Our current data 
show that loss of NQO1 
decreases tumor growth in soft 
agar and increases 
sensitization to anoikis. Thus, 
we hypothesized that depletion 
of tumor-NQO1 levels would 
significantly decrease the ability 
of cells to proliferate. Our data 
show that A549 and H292 
NQO1 knockdown cells had 
significantly lower rates of 
proliferation as compared to 
their respective controls 
(Figures 5 A-B). These data 
suggest that depletion of NQO1 
inhibits cell growth by inducing 
apoptosis caused by 
detachment induced cell death. 
  
     To address the role that 
NQO1 depletion plays in vivo 
tumor growth, varying 
concentrations (1, 2.5 and 5 
 
Figure 5. Loss of NQO1 expression inhibits cell proliferation and in vivo 
tumor growth.  In A and B, A549 and H292 cells were assayed for 
proliferation rates at 0, 24, 48 and 72 h using the CyQuant cell proliferation 
kit (Life Technologies). In C, A549 shNQO1 cells (open symbols) and A549 
shCtr-R (closed symbols) were subcutaneously injected into flanks of 
athymic mice at varying concentrations ((1.0 black), (2.5 blue) or (5.0 red) x 
106) cells. Tumor growth was assessed bi/weekly using calipers. In D, A549 
shNQO1 and A549 shCtr-R cells were injected subcutaneously into flanks of 
athymic mice and tumors were measured bi weekly by caliper measurements 
until a volume of 1000 mm3 was reached. Kaplan-Meir survival analysis was 
conducted using GraphPad Prism 6 software. In E, representative 
photomicrograph of mice in C where mice were injected on the Left flank (L) 
with A549 shNQO1 cells or on the right flank (R) with A549 shCtr-R cells at 
the indication concentration of cells. Shown are mice whose tumors were 
photographed after 32 days. In F, Western Blot for tumor-NQO1 expression 
and PARP-1 cleavage. Samples were harvested in PARP-lysis buffer as 
described in “Materials and Methods”. In A, p values for A549 shNQO1 vs 
A549 shCtr-R cells at 24 h (p = 0.0031), 48 h (p < 0.0001) and 72 h (p = 
0.0004). In B, p values for H292 shNQO1-B vs H292 shCtr-L cells at 24 h (p 
= 0.0070), 48 h (p = 0.0011) and 72 h (p < 0.0001). In C, p values for A549 
shNQO1 vs A549 shCtr-R cells at 5 x 106 cells (p <0 .0006), 2.5 x 106 cells (p 
< 0.0006) and 1.0 x 106 cells (p<0.006). In D, p values for A549 shCtr-R vs 
A549 shNQO1 (p = 0.0083) 
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million) of A549 shNQO1 and A549 shCtr-R cells were implanted subcutaneously into 
athymic mice and tumor growth and overall survival rates were evaluated.  Our in vivo 
xenograft data clearly show that a significant growth disadvantage is observed in A549-
shNQO1 cells at each concentration of cells implanted as compared to A549-shCtr-R 
cells (Figures 5 C and E). In addition to significantly reducing in vivo tumor growth 
rates, the depletion of tumor-NQO1 expression levels in animals bearing A549-
xenografts increased their overall survival as compared to animals bearing A549-shCtr-
R xenografts (Figure 5 D). We also observed that tumor-NQO1 levels remained 
depleted in A549-shNQO1 xenografts as illustrated by our in vivo western-blot analysis 
for NQO1 protein expression (Figure 5 F). 
Interestingly, a substantial difference in 
PARP-1 proteolysis was observed in A549-
shNQO1 tumors as compared to A549-
shCtr-R tumors, further supporting our 
anoikis data that suggest that loss of 
NQO1 leads to increased apoptosis 
(Figure 5 F and Supplemental Figure 
11). 
 
NQO1 depletion reduces the percentage 
ALDHhgh cells in the tumor cell 
population. 
     We have shown that knockdown of 
NQO1 expression in lung cancer cells 
decreased clonogenic growth in vitro and 
tumor growth in vivo. Numerous studies 
have reported that cancer stem cell 
populations are responsible for increased 
tumorigenicity and resistance to 
therapeutics. Thus, we sought to determine 
if NQO1 affected this critical population of 
cells. Previous work has shown that one of 
the most reliable cancer stem cell markers 
is aldehyde dehydrogenase (ALDH) (196, 
197). Although several isoforms of ALDH 
exists, a common assay used to define the 
ALDH(high) stem cell population is the 
Aldeflour assay (196). In our studies we 
tested the hypothesis that NQO1 depletion caused less tumor growth due to depletion 
of ALDH(high) cells. Our data clearly show that there is a significant decrease in the 
ALDH(high) population in A549 shNQO1 cells as compared to A549 shCtr-R cells (Figure 
6). Interestingly, this phenomenon was also discovered to be true in MiaPaCa 




Figure 6. NQO1 depletion causes a decrease in 
ALDHhigh activity. In A, representative flow cytometry 
tracing of A549 shNQO1 and A549 shCtr-R cells analyzed 
for ALDH(high) activity using the Aldefluor Assay Kit from 
“Stem Cell Technologies”. Cells were assayed according to 
the manufacturers protocol as described in “Materials and 
Methods”. DEAB was used as an inhibitor of ALDH(high) 
activity. The percentages shown in each tracing indicate 
the population of cells staining for ALDH(high) activity. In B, 
graphical presentation of A549 shNQO1 and A549 shCtr-R 
cells assayed for ALDH(high) activity. The graph represents 
experiments repeated at least 5 times in duplicate. 
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     Normal cells are under continuous bombardment from intracellular and extracellular 
oxidative stress in the form of ROS (198). Damage caused by uncontrolled oxidative 
stress from lethal levels of ROS can lead to DNA strand breaks, mutation events and 
even cell death (199). Thus, mechanisms that facilitate control over ROS levels are 
uniquely important to cell proliferation and survival. Importantly, normal levels of ROS 
are needed in various cell-signaling events involving cell proliferation as well as 
programmed cell death. It is also of note that specific ROS are critical to many disease 
processes such as aging and cancer (198, 199). Thus, various defense mechanisms 
have evolved to regulate exposure to endogenous and exogenous ROS. These 
mechanisms include the transcription factor Nrf2 that transcriptionally activates the 
expression of numerous down stream target genes that modify and regulate the 
duration and exposure level to ROS (200). The genes activated by Nrf2 include 
glutathione peroxidase, catalase and NQO1. The down stream targets of Nrf2, such as 
NQO1, regulate exposure to ROS from both exogenous and endogenous sources and 
play a critical regulatory role in cell survival and cell death. 
 
     Cancer cells, just as in normal cells, must regulate ROS levels and have adapted to 
exposure to high levels of ROS through the altered expression of specific ROS 
regulatory genes that aid in their survival (201). Catalase for example, is normally 
expressed at high levels in normal tissues, however in tumors its levels are relatively 
low (202). The down-regulation of catalase expression in tumors is not clearly 
understood. However, catalase suppression has been associated with specific tumor 
promoting signaling pathways and resistance to chemotherapeutics (169, 203). 
Interestingly, studies with breast cancer and lung cancer cells have shown that re-
expression of catalase modifies their exposure to ROS levels from their tumor 
microenvironment and ultimately enhances tumor cell death (204, 205). This would 
imply that reversing the expression of specific ROS regulatory genes in cancer cells 
could potentiate a tumor specific cell death.    
 
     Previous studies have implicated NQO1 as a prognostic marker that negatively 
affects patient survival (137, 206). In most of these studies, the poor patient outcome is 
attributed to the existence of 2 prominent NQO1 polymorphisms, referred to as *2 and 
*3. The *2 mutation is more common and involves a C to T point mutation at nucleotide 
position 609. These polymorphisms exist at varying, but small percentages, within the 
population (171). Those patients whose tumors were identified to have the homozygous 
*2 mutation in NQO1, were found to be more susceptible to issues involving 
chemotherapeutic toxicity when exposed to NQO1-detoxified therapeutics such as 
epirubicin (137). In contrast, recent retrospective analyses have shown that elevated 
NQO1 expression in patient tumor versus normal tissue predicts poor patient survival 
(185, 186). We hypothesized, from the latter studies, that tumors elevate NQO1 to 
enhance survival and that reduction of NQO1 could potentially ameliorate the negative 
effects of tumor-NQO1 overexpression on patient outcome.   
 
     In the current study we focused on determining whether decreasing elevated tumor-
NQO1 levels in lung cancer cells would inhibit tumor survival. We chose specific 
readouts, such as anchorage-independent growth, anoikis and in vivo tumorigenesis 
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assays, to make a connection between tumorigenic processes and the role that NQO1 
played in each. Our data clearly show that loss of NQO1, by stable shRNA knockdown, 
significantly affected anchorage- independent growth of lung cancer cells, which is 
hallmark of tumorigenesis. These data suggested that NQO1 overexpression is 
intimately involved in the survival and proliferative capacity of lung cancer cells that 
overexpress NQO1. These data were corroborated by dicoumarol and Mac220 studies 
that showed that treatment with NQO1 inhibitors significantly decreased the growth of 
lung cancer cells in soft agar. In addition to inhibiting growth in soft agar, we showed 
that loss of NQO1 potentiated anoikis, suggesting that cells that were NQO1 depleted 
were more susceptible to detachment induced cell death. This was further supported by 
the increase in ROS that was found in shNQO1 cells versus our control cells which 
correlates with increased anoikis. We also showed that loss of NQO1 decreased both 
cell proliferation and invasion suggesting that knocking down NQO1 decreases the 
tumorigenic potential of lung cancer cells. In contrast to cancer cells, our in vitro data 
show that transient knockdown of NQO1 in non-transformed, non-tumorigenic human 
bronchial epithelial cells (HBECs) did not reduce their short-term viability or long-term 
survival (Supplemental Figure 14).  
 
     Our in vivo studies confirmed that 
stable NQO1 depletion increased 
long-term survival in mice since 
shNQO1 tumors were significantly 
smaller than control tumors, and 
survival of mice bearing shNQO1 
tumors was significantly enhanced as 
compared to mice bearing control 
tumors.  Finally, we show that loss of 
NQO1 substantially reduced the 
ALDH(high) population in lung, 
pancreas and prostate cancers. In 
previous reports it has been 
demonstrated that ALDH(high) activity 
within a tumor population is a reliable 
marker for cells that have a cancer 
stem cell phenotype in a number of 
malignancies (196, 197). 
Interestingly, knockdown of specific 
ALDH isoforms has been linked to 
the loss of stemness and 
tumorigenicity in lung cancer (207). 
Our studies show that loss of NQO1 
reduces the population of cells with 
ALDH(high) activity, suggesting that 
the loss in tumorigenicity seen in 
NQO1 knockdown cells (Figure 5 C-
E) is attributable to the loss of the 
 
 
Figure 7. Model depicting therapeutic approach where 
reduction of NQO1 levels in tumors leads to decreased tumor 
burden in the lungs of cancer patients. In A, NQO1 (blue 
squares) is expressed at normal levels in lung in response to 
oxidative stress. In B, NQO1 (blue squares) is overexpressed in 
tumor cells (black circles) within the lung due to increased necessity 
to inhibit ROS stress. In C, targeting NQO1 in lung tumors leads to a 
decrease in tumor burden in patients with elevated NQO1 levels in 
their lung tumors. In B, cancer stem cells within a tumor will have 
increased ALDH(high) activity. In C, NQO1 knockdown reduces the 
population of tumor cells with ALDH(high) activity. 
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ALDH (high) subpopulation of cells (Figure 6). In summary, we report for that NQO1, a 
gene found overexpressed in many solid tumors, including NSCLC, can be directly 
targeted for therapy since it plays a critical role in the overall growth, invasive potential 
and survival of lung cancer. We hypothesize that NQO1 expression is increased in 
tumors to thwart ROS stress, and that reversing the elevated expression of tumor-
NQO1 leads to increased susceptibility to ROS and reduced tumor burden due to 
anoikis and the loss of the ALDH(high) cell population (Figure 7). These results suggest 
that NQO1 depletion may be an important link in eliminating cancer stem cell 
populations not only in lung cancer, but in other malignancies as well. Finally, these 
data establish the potential for a new clinical approach that targets NQO1 in lung cancer 
patients whose tumor-NQO1 expression levels are often found to be 5-20 times more 
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Supplemental Figure 1. Tumor-NQO1 overexpression leads to poor prognosis 
in lung cancer patients. In A and B, Kaplan-Meier analysis of patient survival 
based on tumor NQO1 expression levels from two different TCGA data sets. Data in 
A included 148 high NQO1 patient tumors (red) and 145 low NQO1 patient tumors 
(black) . Data in B are from 28 high NQO1 patient tumors (red) and 76 low NQO1 
patient tumors (black) . Patients in these studies were grouped into NQO1 low and 




Supplemental Figure 2. shNQO1-B knockdown of NQO1 leads to decreased 
growth in soft agar. In A, Western blot for NQO1 expression in A549 cells stably 
knocked down for NQO1 using lentiviral (shNQO1-B) and compared to A549 
parental, lentiviral vector control (shCtr-L) and A549 shNQO1 (retroviral) 
knockdown cells. In B, A549-shCtr-L and A549-shNQO1-B cells were subjected 
to soft agar assays as described in “Materials and Methods”. The soft agar data 






Supplemental Figure 3. shNQO1-B knockdown of NQO1 in H292 cells 
leads to decreased growth in soft agar. H292-shCtr-L and H292-shNQO1-B 
cells were subjected to soft agar assays as described in “Materials and 
Methods” for H292 cells. The soft agar data presented here are represented in 




Supplemental Figure 4. Dicoumarol inhibits growth of A549 cells in soft agar.  In A, 
Western Blot for NQO1 expression in A549 cells exposed to 50µM dicoumarol for 2 or 24 
hours. A549 sh-NQO1 cells were used as negative control. In B, following dicoumarol 
treatment, cells were liberated by trypsin, enumerated and subjected to soft agar assays as 
described in “Materials and Methods”. In C, quantitative representation of soft agar plates that 
were imaged after 3 weeks using an Epson V700 photo scanner. The enumeration of colonies 




Supplemental Figure 5. Mac220 inhibits growth of A549 cells in soft agar. In A, to 
demonstrate the effect of Mac220 on an NQO1-dependent chemotherapeutic, A549 cells 
were treated for 2 hours with varying doses of ARQ-761 (aka β-Lapachone, B-Lap) in the 
presence or absence of the NQO1 inhibitor dicourmarol (DIC, 50 µM) or Mac220 (5 µM). 
After 2 hours, drug media was removed and fresh media was added. Cells were allowed to 
grow for 7 days prior to evaluation of survival using a Hoescht DNA content assays as 
described previously (9,12). In B, following 24 h treatment with 50 µM dicoumarol or 5 µM 
Mac 220, A549 cells were liberated by trypsin, enumerated and subjected to soft agar 
assays as described in “Materials and Methods”. In C, quantitative representation of soft 
agar plates that were imaged after 3 weeks using an Epson V700 photo scanner. The 




Supplemental Figure 6. Stable overexpression of NQO1 in H596 (NQO1 
null) lung cancer cells causes increased growth in soft agar. In A, 
Western Blot analysis of NQO1 null H596 cells that were stably transfected 
with NQO1 using an LPC-NQO1 retro viral construct or vector control (LPC-
X) as described previously (9). In B, NQO1 enzyme assays were performed 
according to the manufacturers protocol described in “Materials and 
Methods” Shown is a representative quantification of NQO1 enzymatic 
activity performed in triplicate. In C, cells were liberated by trypsin, 
enumerated and subjected to soft agar assays as described in “Materials 
and Methods”. In D, quantitative representation of soft agar plates that were 
imaged after 3 weeks using an Epson V700 photo scanner. The 
enumeration of colonies present in each dish was quantified using ImageJ 




Supplemental Figure 7. Transient knockdown of NQO1 in H596 LPC-NQO1 cells 
causes decreased growth in soft agar. In A, Western Blot analysis of H596 LPC-
NQO1 cells that were transiently transfected with NQO1 siRNA or scramble control 
siRNA and harvested after 48 h as described in “Materials and Methods”. In B, following 
transient transfections cells were liberated by trypsin, enumerated and subjected to soft 
agar assays as described in “Materials and Methods”. In C, quantitative representation of 
soft agar plates that were imaged after 3 weeks using an Epson V700 photo scanner. 




Supplemental Figure 8. shNQO1-B knockdown of NQO1 in A549 cells 
decreases cell invasion. In A, A549 shCtr-R and A549 shNQO1 cells were allowed 
to form spheroids and the spheroids were placed atop of noble agar.  The total area 
was measured after 10 days of culture. In B, A549-shCtr-L and A549 shNQO1-B 
cells were subjected to invasion assays as described in “Materials and Methods”. 
Images and quantitation of invasion distance was performed as described in 




Supplemental Figure 9. Stable overexpression of NQO1 in H596 NQO1-null 
cells causes increased invasion. In A, H596 LPC-X and H596 LPC-NQO1 cells 
were allowed to form spheroids and the spheroids were placed atop of noble agar. 
Spheroids were then subjected to invasion assays as described in “Materials and 
Methods”. In A and B, Images and quantitation of invasion distance was 





Supplementary Figure 10.  Transient knockdown of NQO1 using siRNA 
inhibits invasion of HCC1171 cells. In A, HCC1171 lung cancer cells were 
transiently transfected with control siRNA or NQO1 siRNA as described in 
“Materials and Methods”. After 48 h cells were harvested for Western 
Assays to detect NQO1 expression. In B, following transfection cells were 





Supplemental Figure 11. Stable knockdown of NQO1 in A549 cells causes loss 
of PARP-1 protein expression. Western Blot analysis of A549 shCTr-R and 
shNQO1 tumors harvested from mice at various times in long-term survival studies 
(Figure 5 D). Samples were harvested in PARP-lysis buffer as described in 
“Materials and Methods” and probed for PARP-1 and NQO1.  Blots were also probed 




Supplemental Figure 12.  Knockdown of NQO1 reduces ALDH (high) activity 
in Pancreas cancer cells. In A, representative flow cytometry tracing of 
MiaPaCa shNQO1 knockdown cells and shCtr-R cells analyzed for ALDH(high) 
activity using the Stem Cell Kit from “Stem Cell Technologies”. Cells were 
assayed according to manufacturers protocol as described in “Materials and 
Methods”. DEAB was used as an inhibitor of ALDH(high) activity. In B, graphical 
representation of shNQO1 and shCtr-R cells assayed for ALDH(high) activity. 














































Supplemental Figure 13.  Knockdown of NQO1 reduces ALDH (high) activity in 
Prostate cancer cells. In A, representative flow cytometry tracing of PC3 shNQO1 
knockdown cells and shCtr-R cells analyzed for ALDH(high) activity using the Stem Cell 
Kit from “Stem Cell Technologies”. Cells were assayed according to manufacturers 
protocol as described in “Materials and Methods”. DEAB was used as an inhibitor of 
ALDH(high) activity. In B, graphical presentation of shNQO1 and shCtr-R cells assayed 





Supplemental Figure 14. NQO1 knockdown does not inhibit short-term 
viability our long-term survival of non-transformed human bronchial 
epithelial cells. In A, high levels of NQO1 activity are detected in A549 cells as 
compared to the low levels detected in the non-transformed, non-tumorigenic 
human bronchial epithelial cells (HBECs) using an NQO1 activity kit (ABCAM) as 
described in “Materials and Methods”.  In B, Western-blot analyses of HBECs for 
NQO1 expression following a 48h transient transfection with scramble control 
siRNA or siRNA-NQO1 (Santa Cruz Biotech). In C and D, representative images 
of soft agar assays comparing tumorigenic A549 cells and non-transformed and 
non-tumorigenic HBECs (performed in triplicate) and quantitation of the colonies 
detected. In E, HBECs were subjected to transient transfections with siRNA-
Control or siRNA-NQO1 (SantaCruz Biotech). After 48h, cells were enumerated 
and seeded at a density of 20,000 cells/well in 96 well plates for 24 h. The 
following day short-term viability assays were performed using CellTiter-Glo 
reagent (Progmega). Luminescence was detected using a Synergy-H1 Hybrid 
microplate reader. Relative Luminescence Units were calculated by subtracting 
the blank (media alone) wells from the test wells. In F, HBECs were subjected to 
transient transfections with siRNA-Control or siRNA-NQO1. After 48 h cells were 
seeded in 48 well dishes at a density of 2500 cells/well. Cells were allowed to 
grow for 7 days. After 7 days, long-term survival based on DNA content was 
detected using a Hoescht staining fluorescence assay described in “Materials and 
Methods”. Fluorescence was detected using a Synergy-H1 Hybrid microplate 
reader. Relative Fluorescence Units were determined by subtracting blank wells 
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Cancer stem cells (CSCs) are purportedly a key resistance factor in most solid tumor 
models. Stem cell markers for heterogeneous bulk tumors have been loosely defined in 
the literature for most tumor types with albeit some consensus as to which assays are 
useful in determining whether specific genes are playing roles in the cancer stem cell 
phenotype. In the current study we utilized a tumor spheroid model to determine 
whether NADPH quinone oxidoreductase-1 (NQO1) was requisite in the promotion of 
the cancer stem cell phenotype in non-small cell lung cancer (NSCLC). Our data show 
that stable depletion of NQO1 in A549 and H358 human NSCLC tumor models alters 
their ability to form primary tumor-spheroids. In addition to inhibiting primary spheroid 
formation, the loss of NQO1 also affected serial, secondary and tertiary, spheroid 
formation. Interestingly when NQO1 expression levels were rescued the spheroid 
formation ability of tumor cells was restored. Our data also show that A549 and H358 
tumor spheroids were significantly less proliferative when NQO1 was depleted as 
compared to control cells.  Finally, our data also show that cisplatin refractory A549 
tumor spheroids were rendered significantly sensitized to cisplatin due to NQO1 
depletion, suggesting that removal of NQO1 reduces the stem cell resistant population. 
In summary, the data from these studies, along with our previous findings that show 
NQO1 depletion reduces ALDHhigh activity, strongly support a role for NQO1 as marker 





     Over the past two decades lung cancer has been the leading cause of cancer related 
deaths in the U.S. and worldwide (208). In 2016 it is estimated that more than 158,000 
deaths will occur in the U.S. due to cancer of the lung and bronchus (209). Of the 
221,000 estimated new lung cancer cases that will occur in 2016, 20% will be 
diagnosed as small cell lung cancer (SCLC), with the remaining 80% developing non-
small cell lung cancer (NSCLC) (209-211). Both NSCLC and SCLC have abysmal 5-
year survival rates of 15% and 5 % respectively (208, 209). The major factors leading to 
the poor survival rates observed in lung cancer patients include chemo-resistant 
disease, late stage diagnosis and subsequent spreading of disease (212, 213).  
 
     Interestingly, a number of NSCLC cases have demonstrated that overexpression of 
cytoprotective genes reduces the effects of commonly prescribed chemotherapeutics 
and radiation therapy (146). Of those genes with increased expression, 
NAD(P)H:quinone oxidoreductase 1 (NQO1), has been found to be overexpressed in 
~60% of all NSCLC cases (117, 214). Additionally, the presence of lung cancer stem 
cells (CSCs) has become increasingly appreciated as a mechanism to enhance the 
tumorigenic properties of NSCLC. The ability of CSCs to initiate tumorigenesis, 
circumvent conventional therapies, and metastasize to distant locations makes targeting 
CSCs a promising strategy in the fight to improve patient survival. 
 
     NQO1 is a phase II detoxifying enzyme that is responsible for the neutralization of 
dangerous intracellular quinones, and in general serves to scavenge reactive oxygen 
species (ROS) (192, 215). Recently, there has been increased attention given to NQO1 
overexpression in a number of tumor malignancies as it has been shown to be a useful 
therapeutic target. Treatment with the quinone analog, β-lapachone (currently ARQ-761 
in clinical trials), has shown promise inducing death in a tumor-specific manner. ARQ-
761 enters into a futile cycle with NQO1 that leads to ROS accumulation, poly ADP 
ribose polymerase hyperactivation, nucleotide depletion, and ultimately cell death (170, 
175, 216). While substantial data exists to support NQO1 overexpression as a valid 
drug target, the mechanism by which NQO1 promotes the tumorigenic phenotype is not 
well understood. 
 
     In 1997, Bonnet and Dick were the first to describe the concept of a cancer stem cell 
when they demonstrated that a small leukemic cell population, defined by a set of 
cluster differentiation markers (CD34+CD38-), were able to establish the disease at low 
numbers in comparison the whole tumor population (217). Since the original 
identification of a leukemic CSC, researchers have discovered and defined CSCs in a 
number of other malignancies including breast, brain, and prostate cancers (218-220). 
To this point, a number of CSC markers have been used in an attempt to define the 
CSC population in NSCLC including CD133, aldehyde dehydrogenase (ALDH), and 
side population (221-223). Of the large number of markers used to define NSCLC 
CSCs, ALDH activity has shown the most promise in defining the small tumorigenic 




     In an attempt to better 
understand NQO1’s role in 
tumorigenesis and tumor 
maintenance, our laboratory has 
begun to investigate the 
relationship between NQO1 and 
maintenance of the cancer stem 
cell-like phenotype (Figure 1). 
Previously, we published that 
NQO1 is important for a number of 
malignant characteristics including 
tumorigenesis, anoikis resistance, 
invasion, and even regulation of 
ALDH activity (224).    
     
     To expand upon the novel 
findings that showed the activity of 
the stem cell marker ALDH was 
reduced, suggesting less cancer 
stem-like cells, we have conducted 
new studies that link NQO1 as 
having a vital role in the CSC 
phenotype of NSCLC. Here, we 
demonstrate that NQO1 is necessary for in vitro serial spheroid formation, therapeutic 
resistance, and in vitro limiting dilution tumor formation. Our data demonstrate for the 
first time that NQO1 is vital to the maintenance of the CSC population and that reducing 
NQO1 expression levels in tumors may prove to be a useful therapeutic approach for 
reducing chemo-resistant NSCLC CSC. 
 
Materials and Methods 
 
Cell Culture 
     A549, H358, and H596 cell lines were grown in Dulbecco’s Modified Eagles Media 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and 1% L-glutamine. Cell 
lines were cultured at 37° C with 20% oxygen and 5% carbon dioxide prior to spheroid 
culture. Cells were passaged weekly and supplemented with fresh media. 
 
Stable NQO1 protein knockdown 
     A549 and H358 cell lines underwent stable NQO1 knockdown as previously 
described (224). Briefly, the shNQO1 retroviral vector was purchased from Open 
Biosystems (RHS1764-9691437), and lentiviral particles were purchased from Santa 
Cruz Biotechnology (sc-37139). The stable knockdown cell lines (shNQO1, shNQO1 
[lenti]) and empty vector controls (shCtr, shCtr [lenti]) were created for both A549 and 
H358 cell lines by viral infection in polybrene supplemented media containing either 
shNQO1 or shCtr viral particles. Following viral infection, cells were then put in limited 
dilution under puromycin (2 µg/ml) selection, and screened for NQO1 expression via 
 
 
Figure 1. Characteristics of cancer stem cells and their 
progenitors. Cancer stem cells are believed to responsible for giving 
rise to the heterogeneous tumor population, as well as maintain an 
infinite pool of cancer stem cells through the processes of asymmetric 
and symmetric division, respectively. The two distinct populations that 
arise from these divisions include the cancer stem cell population (beige 
cell), as well as the progenitor population (blue cell). Cancer stem cells 
harbor a number of traits including self-renewal capabilities, tumor 
initiation, metastatic potential, chemoresistance, and maintenance of an 
undifferentiated phenotype. In contrast, the progenitor population is 




Western blot.  A549-shNQO1 and H596 cell lines were forced to express NQO1 via the 
retrovrial vector (LPC-NQO1) or the empty vector control (LPC-X) as previously 
described. Cells were then put into limited dilution and evaluated for NQO1 expression 
via Western blot. 
 
Western blotting 
     Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF 
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room 
temperature, and then incubated overnight with β-actin (1:5000, Santa Cruz 
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with 
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was 
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa 
Cruz Biotechnology), as well as 1:1000 dilutions of monoclonal Shh, SOX2, and Nanog 
antibodies (Cell Signaling). Pierce ECL western blotting substrate (Thermo Scientific) 
was used to visual bands on Hyblot-CL autoradiography film (Denville Scientific) 
 
NQO1 Activity Assay 
     NQO1 enzyme activity was performed as previously described (224). Briefly, 2x107 
cells of each cell line were collected. Pellets were solubilized in extraction buffer for 20 
min, after which they were centrifuged at 18,000 x g for 20 min at 4° C. Supernatants 
were collected into eppendorf tubes at stored at -80° C. Samples were then run 
according to the manufacturers protocol for the NQO1 activity assay kit from Abcam. 
Results were read at an absorbance of 440 nm every 20 seconds for 5 minutes utilizing 




    Low-attachment culture plates were produced by coating the plates (Corning) with a 
0.2% poly-hema/95% ethanol solution. Plates were incubated at 60° C overnight and 
allowed to dry. The process was then repeated a second time. Plates were washed 
twice with milli-Q water immediately prior to use. Cells were trypsinized and treated with 
trypsin neutralizing solution (1:1 ratio) prior to being counted using a hemocytometer. 
160,000 cells were then plated in the low attachment 150 mm plates in 0.25% FBS 
DMEM supplemented with 1% L-glutamine. Cells were allowed to form spheroids over 
14 days, at which time they were collected, trypsinized into single cell suspensions, and 
utilized for the respective assay. For spheroids grown in methylcellulose suspension, 
1% methylcellulose in 0.25% FBS DMEM was further diluted in 1:1 0.25% FBS DMEM 
and cells were added to this mixture. The cell suspension was then plated on low 
attachment plates and imaged 2 weeks later for quantification. 
 
Extreme limited dilution assay 
     Low attachment 96-well plates were prepared by treating plates with 0.2% poly-
HEMA in 95% ethanol and allowing them to dry overnight. This process was repeated a 
second time to ensure proper application. Prior to plating the 96-well plate was washed 
twice with sterile milli-Q water. Cells were trypsinzed, counted, and plated in 0.25% 
FBS-containing DMEM at densities of 40, 120, 360, and 720 cells per well. Each dilution 
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was performed in 24 wells. Cells were allowed to expand over three weeks (21 days), at 
which time the wells were examined for the presence of spheroids. A well containing a 
spheroid was counted as one, multiple spheroids per well did not increase the number 
of positive wells. The number of positive wells per dilution was then entered into the 
extreme limited dilution cancer stem cell frequency calculating software available at 
http://bioinf.wehi.edu.au/software/elda/. 
 
Drug Treatment Studies 
   Spheroids were collected after 14 days and trypsinized into single cell suspension. 
Cells were counted and suspended in DMEM media supplemented with 0.25% FBS and 
1% L-glutamine at a concentration of 10,000 cells/ml. 200 µl of cell suspension was 
then added to each well. Cells were allowed to attach overnight, and the following day 
were treated with 0, 2.5, 5, and 10 µM cisplatin dissolved in DMSO. Stock 
concentrations of 2.5, 5, and 10 mM cisplatin were diluted 1:1000 in 0.25% FBS DMEM 
supplemented with 1% L-glutamine and incubated on cells overnight. Each dose was 
performed in 8 replicates for each dose tested. Twenty-four hours after initial treatment, 
cell viability was assessed using Cell-Titer Glo (Promega), according to the 
manufacturer’s protocol utilizing the Synergy-H1 Hybrid Reader. 
 
Cell Proliferation Assays 
     Spheroids were mechanically (pipetting) and enzymatically (trypsin) broken down 
into single cell suspension. Cell suspension was then treated 1:1 with trypsin 
neutralizing solution to inactivate the trypsin. Cells were then quantified using a 
hemacytometer and suspended in 0.25% FBS DMEM at a concentration of 10,000 
cells/ml. Utilizing 96-well plates, 100 µL of each cell suspension was plated in 5 wells, 
and the respective plate was collected at the time points of 0, 24, 48, and 72 hrs. At this 
time 1e6 cells was also collected in a micro-centrifuge tube in order to later generate a 
standard curve. Collected plates were washed once with PBS, aspirated, and froze at -
80° C, until all plates were collected and ready to be read. Plates were quantified using 
CyQuant Cell Proliferation Assay (Thermo Fisher), according to the manufacturers 
protocol utilizing the Synergy-H1 Hybrid Reader. 
 
Quantitative real-time qRT-PCR 
     Total RNA was isolated utilizing the Trizol extraction method (225). cDNA was 
created from the total RNA sample utilizing iScript cDNA Synthesis Kit (Bio-Rad). qRT-
PCR was performed using primers designed for NQO1 (Fwd- 5’-
CCAGATATTGTGGCTGAACAAA-3’; Rev- 5’-TCTCCTATGAACACTCGCTCAA-3’), 
and SsoAdvanced Universal SYBR Green Supermix (Bio-Rad). Samples were analyzed 
using the CFX Connect Real-time qRT-PCR System (Bio-Rad). Relative expression 
values were calculated utilizing double delta Ct analysis.  
	
Statistical analysis 
     Data analyses were performed using GraphPad Prism 6 software. Statistical 
significance was determined by using the Student t tests, and P values from these 







NQO1 is essential for in vitro spheroid formation 
     In order to evaluate the stemness of a cancer cell population, it is common to utilize 
the spheroid formation assay as it demonstrates the ability of cells to replicate in a 
detached environment, one of the hallmarks of the transformed phenotype (46, 226-
228). To determine the role of NQO1 in stemness using spheroid assays as an 
assessment tool, NQO1 levels were 
reduced in both the A549 and H358 
NSCLC cell lines via the stable 
retroviral expression of shRNA toward 
NQO1, (Figures 2A & 2C) respectively. 
As expected from our previous 
experience in creating stable NQO1 
knockdown cell lines, the reduction in 
NQO1 protein expression correlated 
with a decrease in NQO1 activity 
(Figures 2B & 2D). Subsequently, we 
demonstrated that the reduction of 
NQO1 protein levels leads to a near 
total loss in primary spheroid formation 
in A549 (Figure 3A) and H358 (Figure 
3C) cell lines. A549-shCtr cells were 
able to form ~30 spheroids per field of 
view (50X magnification), where the 
A549-shNQO1 population 
demonstrated a significantly reduced 
ability to produce spheroids (Figure 
3B). Interestingly, the inability of A549-
shNQO1 cells to form spheroids was 
not a result of significant cell death, as 
trypan blue exclusion assays and 
analysis of apoptotic endpoints (PARP-
1 cleavage and AIF expression), show 
no significant difference over time (Supplemental Figure 1).  Additionally, this data was 
recapitulated using a second, lentiviral driven shRNA toward NQO1 with similar results 
(Supplemental Figure 2A) The H358 cell line does not appear to have a robust sphere 
forming ability as compared to A549 cells as they form fewer spheres per field of view. 
However, a significant difference exists between the H358-shCtr and H358-shNQO1 
populations (Figure 3D). To confirm that our spheroids were forming because of clonal 
expansion and not forming due to aggregation, we also formed spheroids using 
methylcellulose and found a similar significant difference in spheroid forming ability in 
A549 cells that were depleted in NQO1 expression versus controls (Supplemental 
Figure 2B). In an effort to further confirm NQO1’s importance in spheroid formation, the 
 
Figure 2. Stable knockdown of NQO1 expression in NSCLC 
cells reduces NQO1 activity. In A, A549 lung adenocarcinoma 
cells were evaluated for NQO1 expression following retroviral 
transfection of shRNA targeted at NQO1 (A549-shNQO1), or 
empty vector control (A549-shCtr). In B, A549-shCtr and A549-
shNQO1 cell lines were analyzed for NQO1 activity, where loss 
of NQO1 correlated with a significant decrease in NQO1 activity 
(**** = p <0.0001). In C, the lung cancer cell line, H358 was 
evaluated for NQO1 protein expression following retroviral 
transfection of shRNA directed toward NQO1 (H358-shNQO1), 
or the empty vector control (H358-shCtr). In D, H358-shCtr and 
H358-shNQO1 cell lines were evaluated for NQO1 activity, and 
demonstrated that loss of NQO1 protein expression correlated 
with a significant decrease in NQO1 actvity (**** = p <0.0001; *** 




NQO1 inhibitor, dicumarol, was added to the media 
of A549-shCtr and H358-shCtr cultures and 
monitored for sphere formation (Supplemental 
Figure 3).  
 
     In addition, we validated the spheroid assay as a 
method by which to enhance the CSC population 
through the evaluation of the known stem cell 
markers, Sox2, Shh, and Nanog. We determined 
that spheroid culture increased the expression of 
each marker in comparison to normal (attached) 
culture conditions, that was subsequently 
decreased following differentiation culture 
conditions in 10% FBS containing media 
(Supplemental Figure 4). These results thus 
validate the spheroid culture method as a means to 
enhance the CSC population in vitro.  
 
     Interestingly, when we evaluated the expression 
of NQO1 in spheroids, we noticed the expression of 
NQO1 protein in the A549-shNQO1 population 
remained reduced in comparison to A549-shCtr 
spheroid cells (Supplemental Figure 5A), however 
there was an increase in NQO1 mRNA in the A549-
shNQO1 population, as determined by real-time 
qRT-PCR (Supplemental Figure 5B). The level of 
NQO1 mRNA expression remained significantly 
reduced in comparison to the A549-shCtr cell line, however a significant increase was 
noted in comparison to A549-shNQO1 cells plated in 2D culture (A549-shNQO1 2D). 
These results indicated that NQO1 expression may be vital to spheroid formation, as 
those A549-shNQO1 cells that are capable of forming spheroids have a robust increase 
in NQO1 expression in comparison to A549-shNQO1 cells grown in attached conditions.   
Additionally, this data demonstrate that the spheroid culture enhances the CSC 
population, and that NQO1 reduction severely inhibits the ability of NSCLC cell lines to 
initiate spheroid formation.  
 
NQO1 is necessary for serial in vitro sphere formation 
     CSC properties include the ability to divide asymmetrically in order to continually 
produce both a CSC population as well as a population of proliferative progenitor cells 
(229). This allows for the CSC population to continually perpetuate its tumor-initiating 
capabilities following gross reduction of total tumor cell numbers. In an effort to 
demonstrate the presence of CSCs within the A549 and H358 cell lines, serial tumor 
sphere formation assays were performed. Primary spheres were collected and single 
cell suspensions were made that were then placed back into the sphere forming assays. 
This process was carried out until tertiary spheres were formed. Given that both the 
A549-shNQO1 and H358-shNQO1 cells were severely hindered in their primary sphere 
Figure 3. NQO1 depletion reduces primary 
tumor spheroid formation. In A and B, are 
representative images of primary spheroid 
formation for both A549 and H358 cell lines, 
respectively. A549-shCtr cells (A, top panel) 
robustly form primary spheroids in comparison 
to the A549-shNQO1 cell lines (A, bottom 
panel). In the H358 cell line, again the H358-
shCtr cell line (B, upper panel) has an 
increase in the number of primary spheroids 
formed in comparison to H358-shCtr (B, lower 
panel). Primary spheroid counts are quantified 
for A549 and H358 in C and D, respectively 




formation, it was not surprising that their 
ability to form secondary and tertiary 
spheres was also restricted (Figures 4A & 
4B, respectively). In the case of the A549 
cell line, secondary and tertiary A549-
shNQO1 spheres formed at significantly 
lower numbers than A549-shCtr cells. 
These data clearly show that there exists 
an essential role for NQO1 in serial 
perpetuation of tumor spheres. This finding 
is further supported by data obtained from 
the H358 cell line. H358-shCtr cells show a 
slight increase in the sphere forming ability 
upon serial plating, where H358-shNQO1 
lose tertiary sphere forming abilities, a 
more supportive finding for NQO1’s role in 
serial sphere formation than what is seen 
in A549 cells. Interestingly, in a second 
H358-shNQO1 clone that has greater 
expression of NQO1, primary sphere 
formation remains equal to what is seen in 
controls (Supplementary Figure 6). These 
data suggest the possibility that a threshold 
of NQO1 expression exists which allows 
serial formation of tumor spheres. 
 
     In addition to serial spheroid assays, 
NQO1 rescue experiments were performed 
to definitively demonstrate NQO1’s 
necessity in spheroid formation. A549-
shNQO1 cells were forced to express 
NQO1 via retroviral vector, or the empty 
vector control. It can be seen in Figure 4C 
that the level of NQO1 expression is comparable to parental A549 cell line (left panel), 
and the re-expression of NQO1 results in a significant increase in spheroid formation in 
comparison to the control vector (Figure 4D). Furthermore, we utilized the NQO1-null 
NSCLC cell line, H596 that harbors the *2 polymorphism. We then drove the expression 
of NQO1 utilizing the retroviral NQO1 vector and evaluated the sphere forming ability in 
comparison to the empty vector control (Figure 5). These results recapitulate what was 
observed when NQO1 levels were rescued in the A549 cell line that is the presence of 
NQO1 significantly increases the sphere forming ability of H596 LPC-NQO1 cells in 
comparison to its H596 LPC-X (NQO1-null) control. 
 
     Limited dilution assays are often performed in order to determine the tumor initiating 
cell frequency within a cell population (228). In order to determine the frequency of 
CSCs within the A549 and H358 cell lines, both cell lines were placed in an extreme 
Figure 4. Loss of NQO1 expression reduces serial 
spheroid formation, and re-expression of NQO1 
rescues tumor-spheroid forming ability. The self-
renewal capabilities of lung cancer stem cells were 
assayed via a serial spheroid formation assay. In A, A549-
shCtr cells form similar numbers of spheroids in primary 
(black bars), secondary (light grey bars), and tertiary 
generations (dark grey bars), where the A549-shNQO1 
cells form significantly fewer spheroids in each generation 
(* = p =0.0018, # = p = 0.0102, ∞ = p < 0.0001). The H358 
cell line, as seen in B, shows similar results (* = p =0.0035, 
# = p = 0.0449, ∞ = p < 0.0001).  In C, Western blot 
analysis of A549-shNQO1 cells transfected with the 
retroviral NQO1 vector in an effort to induce re-expression 
of NQO1 protein. In D, primary spheroid formation in NQO1 
re-expressing A549-shNQO1 cells. The rescued NQO1 
expression induced a significant increase in the formation 




limiting dilution assay. Results from this 
assay demonstrate that in the A549 cell 
line, those cells in which NQO1 is present 
have an approximate 12-fold increase in 
the presence of cancer stem cells in 
comparison to the shNQO1 cell line. This 
was also true for the H358 cell line 
however to a lesser degree (~ 2-fold) 
(Table 1).  These results suggest that 
NQO1 is vital to maintenance of the cancer 
stem cell population, which is in agreement 
with previously published data (224).  
 
NQO1 knockdown inhibits proliferation, 
increases chemotherapeutic resistance 
of NSCLC tumor spheroids 
     Increased cellular proliferation is often 
observed in tumor cells and previous 
studies have indicated the rapid 
proliferative capacity in various lung cancer 
cells. However, we assessed the 
proliferative capacity cells that were no 
longer attached to plastic to determine if 
NQO1 expression mattered in the cells 
ability to grow in 3D-tumor spheroid 
culture. Our results show that indeed 
NQO1 expression mattered since tumor 
spheroid shCtr cells were 
significantly more proliferative as 
compared to shNQO1 cells for 
both A549 and H358 cell lines 
(Figures 6A and 6B).   
 
     A hallmark of the CSC 
phenotype is the inherent 
resistance to chemotherapy. Given 
that NQO1 has been described to 
protect against chemotherapy in 
malignant cells, as well as 
protecting in chemotherapy-
induced toxicities in normal cells, 
we hypothesize that spheroids 
expressing NQO1 will be protected 
against cisplatin induced cell death 
(146, 167, 230-232). In order to 
test this, spheroids were 
Figure 5. Overexpression of NQO1 in NQO1 null H596 
cells enhances tumor spheroid formation. The NQO1 
null lung cancer cell line was forced to over-express NQO1 
via retroviral vector and subjected to the spheroid formation 
assay. NQO1 expression in the LPC-NQO1 cell line was 
confirmed via Western blot in A. In B, the numbers of 
spheroids formed per field of view were quantified in the 
parental, LPC-X, and LPC-NQO1 H596 cell lines. In C, 
representative images corresponding to the quantification 
found in B (** = p =0.0007; ** = p= 0.0078). 
	
  
Table 1. Cancer stem cell frequency in A549 and H358 cells with or 
without shNQO1 expression. Quantification of the number of cancer 
stem cells present in the cell populations that have been examined was 
carried out utilizing an in vitro extreme limited dilution assay. This assay 
requires plating limited dilutions of cells in low attachment conditions, 
and examining wells for spheroid formation. Wells with at least one 
spheroid were counted as a positive well for the corresponding dilution. 
The results were then analyzed using Extreme Limited Dilution Analysis 
(ELDA) software. The resulting CSC frequencies demonstrate a marked 
increase in the CSC population found in A549-shCtr and H358-shCtr in 




dissociated into single cell 
suspension and plated at a 
density of 1,000 cells per well in 
a 96-well plate. The following 
day, the media was removed and 
media containing 0, 2.5, 5.0, or 
10 µM cisplatin was added to the 
cells. The treatment of tumor 
spheroids with cisplatin lasted 24 
h, after which the Cell-Titer Glo 
kit was used to measure cell 
viability. The data presented in 
Figures 6C and 6D demonstrate 
that for both A549 and H358 
spheres, the expression of 
NQO1 protects against the 
cytotoxic effects of cisplatin at all 
doses administered. The control 
groups for both cell lines were 
used to normalize the data, as 
there was an observed increase 
in viability (greater than 100% 
viability, data not shown), which 
is most likely due to an increase 
in cell numbers. These data 
suggest that specific refractory 
subpopulations within bulk 
NSCLC tumors are resistant to 
chemotherapeutics in part due to 
NQO1 expression levels, and 
that cisplatin-resistant 
populations of CSC within A549 
and H358 bulk tumors could be 





     It is generally accepted that a tumor is a population of many diverse cells that have 
various roles in the survival of the heterogeneous bulk tumor (233, 234). One 
purportedly critical cell type/population within the bulk tumor is thought to be the tumor-
initiating cell or CSC that gives rise to chemoresistant cell populations, and are thought 
to be responsible for latent disease resulting in tumor recurrence, metastasis and poor 
prognoses (235-237). This specialized population of cells is understood to have features 
similar to those of normal stem cells including the ability to repopulate an entire 
population of diverse cell types. Thus, CSCs allow the continual self-renewal and 
 
Figure 6. NQO1 depletion increases sensitization to cisplatin 
treatment and inhibits spheroid-cultured cell proliferation. In A, A549-
shCtr and A549-shNQO1 primary spheroids were dissociated, plated, and 
subsequently treated with cisplatin the following day at the given 
concentrations. Cell viability was computed by comparing the percent of 
A549-shNQO1 survival to that of the A549-shCtr cell line. After 24 hours of 
cisplatin exposure, there was a significant difference in the surviving 
fraction of cells in the A549-shCtr population in comparison to the A549-
shNQO1 cell line (* = p <0.05; ** = p =0.0076). In B, the same experiment 
was carried out comparing the H358-shCtr and H358-shNQO1 cell lines 
with similar results, where the H358-shNQO1 cell line was more 
susceptible to cisplatin treatment than the H358-shCtr cell line (** = p 
<0.005). In C, A549-shCtr and A549-shNQO1 cells grown in spheroid 
conditions were assayed for cellular proliferation. Spheroid cells were 
plated, collected at the specified time points, and enumerated using the 
CyQuant Cell Proliferation Assay (Thermo Fisher). At each time point a 
significant reduction in cell numbers was observed (* = p <0.05). In D, the 
same cell proliferation assay was carried out using the H358-shCtr and 
H358-shNQO1 cell lines. Here, again, there exists a statistically significant 
reduction in cell proliferation in the H358-shNQO1 cell line in comparison 
to the H358-shCtr cell line (* = p <0.05). 
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propagation of the CSC population. Many scholarly endeavors have been made over 
the past thirty years to identify and characterize the CSC phenotype within each tumor 
type. These efforts have led to the development of new therapeutic strategies for 
treatment of various cancers (238-240). 
     The identification and dissociation of the cancer stem cell population from the bulk 
tumor population has been primarily accomplished using markers for stemness. 
Although no iron clad pattern has developed over the years to allow a cook book 
determination of which population of cells within a bulk tumor represent the CSCs for 
that tumor, many studies have developed protocols using various stemness markers as 
strategies to collect these unique cell population. In breast cancer the most common 
stemness markers used in the isolation of CSCs include CD44high CD24low populations 
as well as populations that express ALDHhigh activity and SOX2 expression (241, 242). 
While in lung cancers ALDHhigh activity, along with Notch expression have been more 
closely linked to CSC population in lung cancer patients whose tumors recur, 
metastasize and are refractory to therapy (196, 243).     
 
     In addition to the heavy utilization of CSC markers, various tissue culture and 
propagation methodologies have been developed to isolate or enrich for CSC 
populations. For example, the 3D tumor spheroid model has become a staple amongst 
assays used to study drug efficacy, as well as the CSC phenotype. The spheroid model 
is believed to be more representative of tumor growth in vivo and thus its utilization has 
expanded to involve drug efficacy studies as well as isolation of CSC for analysis (35, 
244).  
 
     In our recent studies we showed that NQO1 depletion in the general population of 
A549 and H292 NSCLC tumor cells correlated with loss of ALDHhigh activity (224). We 
also found that NQO1 depletion inhibited proliferation, invasion and growth in vivo. 
Those data were the first to indicate that tumor-NQO1 levels were linked to 
tumorigenesis, and that NQO1 may be associated with the CSC phenotype. In the 
current study we compared tumor spheroid forming ability in cells with or without NQO1. 
In both our shNQO1 knockdown models we found that NQO1 depletion reduced the 
ability of NSCLC cells to form tumor spheroids and their subsequent ability to form 
secondary and tertiary spheroids was significantly inhibited by the loss of NQO1. 
Interestingly when NQO1 was rescued in our NQO1 knockdown cell lines tumor 
spheroid formation was restored. In addition to NQO1 rescuing NQO1 knockdown cell 
lines, we also show that establishing NQO1 expression in NQO1 null cell lines allowed 
for a significant increase in the spheroid forming ability of NQO1 null NSCLC cell line 
H596.  
 
     In support of NQO1 enhancing the CSC population, we demonstrate that spheroid 
culture enhances the expression of known stem cell markers SOX2, Shh, and Nanog. 
Interstingly, these results are observed in both our A549-shCtr and A549-shNQO1 cell 
lines. When evaluating the expression of NQO1 in our spheroids we notice an 
increased, yet significantly less, expression of NQO1 in our A549-shNQO1 cell line in 
comparison to control. This argues the point that in order for A549-shNQO1 to survive 
and expand under spheroid conditions, increased expression of NQO1 is vital. We 
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postulate that the increased expression of NQO1 in our knockdown line is the reason 
we observe spheroid formation in the A549-shNQO1 cell line and an increase in stem 
cell markers during spheroid culture. These data and the loss of ALDHhigh activity in our 
previous work, strongly suggest that NQO1 is a CSC marker for NSCLC. 
     Finally, we investigated the effect that NQO1 depletion had on chemotherapeutic 
resistance using tumor spheroids. Our data show that shCtr spheroids were resistant to 
cisplatin while shNQO1 spheroids were sensitized to cisplatin treatment. These data 
suggest that depleting NQO1 expression reduces the drug resistant cell population from 
the population of cells rendering them more sensitive to chemotherapy.  
 
     In summary our data provide a sound rationale for developing therapeutics for 
tumors that overexpress NQO1 focusing on decreasing NQO1 expression to eliminate 
the CSC population. Possible strategies may include tumor targeted siRNA strategies to 





Supplemental Figures  
Supplemental Figure 1. Spheroid culture does not affect cell viability. In A, 
the viability of cells in spheroid culture was evaluated via trypan blue exclusion 
over the two-week culture period. There was no obvious difference in cell 
viability between the A549-shCtr and A549-shNQO1 cell lines at anytime over 
the course of observation. In B, cells in spheroid culture were evaluated for 
apoptosis induction by evaluating PARP1 cleavage, as well as AIF induction. 
A549 treated with 0.5 uM staurosporin [A549 (0.5 µM Stauro] served as a 
positive PARP1 cleavage positive control. There was no apparent induction of 
PARP1 cleavage, as well as no obvious increase in AIF expression over the 







Supplemental Figure 2. Loss of NQO1 via lentiviral shRNA inhibits 
spheroid formation, and spheroid formation is a result of clonal 
expansion. In A, Western bot analysis of lentiviral-shRNA knockdown of NQO1 
[A549-shNQO1 (lenti)] in comparison to the A549 control cell line [A549-
shNQO1 (lenti)] (left panel). In B, spheroid assay of A549-shCtr (lenti) and 
A549-shNQO1 (lenti) demonstrating a significant loss of spheroid formation with 
NQO1 reduction (** = p = 0.0066). In C, A549-sh-Ctr and A549-shNQO1 cells 
were tested for clonal spheroid forming ability in the presence of 1% 
methylcellulose, diluted 1:1 in 0.25% FBS/DMEM, as an alternative to 0.25% 
FBS/DMEM medium. Data show significant loss in spheroid forming ability in 
the A549-shNQO1 cell line in comparison to control, similar to what was 





Supplemental Figure 3. Inhibition of NQO1 activity results in loss of 
spheroid generating capabilities. In A, parental A549 cells were tested for 
their spheroid forming capabilities in both the presence and absence of the 
NQO1 inhibitor, dicoumarol. Cells were plated for the spheroid assay and 
treated with either vehicle control, or 50 µM dicoumarol and allowed to 
incubate for 2 weeks. Following incubation, the number of spheroids formed 
was enumerated. The inhibition of NQO1 leads to a significant decrease in 
the sphere forming abilities of the A549 cell line. In B, the same experiment 








 Supplemental Figure 4. Spheroid cultured cells increase expression of stem cell 
markers, and are lost upon differentiation. A549-shCtr and A549-shNQO1 cells were 
pelleted prior to spheroid plating (shCtr and shNQO1), following two weeks of spheroid culture 
(shCtr 1° Sphere and shNQO1 1° Sphere), and following one week of differentiation in 10% 
FBS containing DMEM in an attached setting (shCtr 1° Sphere differentiated and shNQO1 1° 
Sphere differentiated). Western blot analysis was performed in order to visualize the 
expression of known stem cell markers SOX2, Shh, and Nanog. It was observed that there 
was an increase in the stem cell markers as a result of spheroid culture in both the A549-shCtr 
and A549-shNQO1 cell lines. The stem cell marker expression was subsequently decreased 






Supplemental Figure 5. Spheroid culture conditions induce NQO1 expression 
in A549-shNQO1 cells. Both A549-shCtr and A549-shNQO1 cells grown in spheroid 
culture for 2 weeks were assayed for NQO1 expression. In A, Western blot analysis 
demonstrating decreased expression of NQO1 in A549-shNQO1 spheres in 
comparison to A549-shCtr spheres. In B, real-time qRT-PCR analysis demonstrating 
a marked increase in NQO1 mRNA expression in spheroid cultured cells (A549-
shNQO1) in comparison to A549-shNQO1 cells grown in attached conditions (A549-
shNQO1 2D). (*** = p =0.0009) Additionally, it should be noted that the expression of 
NQO1 mRNA in the A549-shNQO1 sphere cultured cells remains significantly 





Supplemental Figure 6. Spheroid formation is dependent on NQO1 expression. In A, 
NQO1 expression was evaluated in the parental, shCtr, shNQO1, and 4C20 (second 
clone) H358 cell lines. The 4C20 clone expresses a greater amount of NQO1 than that of 
H358-shNQO1, and therefore was evaluated for its sphere forming abilities in B. In B, is 
the quantification of the spheroid formation assay, including our 4C20 cell line. It can be 
seen that with an increase in NQO1 expression there is an increase in spheroid formation, 







Summary and Conclusions 
Summary 
 
     The primary focus, for studies regarding cancer and NQO1, has been placed on 
exploiting NQO1 as a tumor-specific drug target. The work to date in this research area 
has provided a strong base of preclinical data, from which several clinical trials are now 
being conducted. Despite the exhaustive interrogation into NQO1 as a tumor-specific 
drug target, there has been little to no investigation into deciphering the antioxidant’s 
role in the promotion and progression of cancer. The work presented in this dissertation 
probed into the role NQO1 plays in (1) promoting tumorigenesis and (2) maintaining the 
CSC population in NSCLC. Our results help to fill in the knowledge gap on the 
supportive role NQO1 overexpression is playing in tumor initiation and progression. 
 
     In Chapter 2, we present our initial study investigating whether NQO1 plays a 
supportive role in tumor initiation and progression in NSCLC. We began with 
determining whether NQO1 is necessary to maintain a transformed phenotype. This 
characteristic was assessed using a soft agar colony formation assay. This assay 
demonstrates the ability of transformed cells to grow in a detached environment, and it 
was observed that decreased expression of NQO1 severely impacted colony formation 
(Chapter 2, Fig. 2A-D). These results indicate that, without increased expression of 
NQO1, a phenotypic change occurs in which the cells have a reduced ability to 
proliferate in anchorage-independent scenarios. 
 
     Next, the invasive capabilities of NSCLC cell lines were analyzed by performing the 
spheroid invasion assay. When spheroids were implanted within a collagen I matrix, it 
was observed that NQO1 was once again playing a positive role in promoting tumor cell 
invasion. This characteristic was lost upon reduction of NQO1 (Chapter 2, Fig. 3A-D). 
These results suggest that NQO1 has a supportive role in the promotion of tumor cell 
invasion, and it can be postulated, although not shown in this study, that NQO1 may be 
aiding in the formation of metastasis as invasion is a crucial step in the establishment of 
metastatic growths (245). 
 
     NQO1 has been reported to function as a reactive oxygen species scavenger, and it 
is well known that detachment from matrix can lead to increased reactive oxygen 
species production(31, 230, 246). Given that we observed near complete loss of colony 
formation in soft agar, we proceeded to evaluate the level of reactive oxygen species in 
our cell lines. We determined that under detached conditions cells with their full 
allotment of NQO1 had significantly lower levels of reactive oxygen species in 
comparison to those in which NQO1 expression was reduced (Chapter 2, Fig. 4A,B). In 
conjunction with these findings, we demonstrated that the detachment of NSCLC cells 
from matrix also resulted in an increase in anoikis, or detachment-induced cell death 
(Chapter 2, Fig. 4C,D). These results demonstrate the importance of NQO1 in the 
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survival of NSCLC in detached environments, such as those encountered when 
disseminated cancer cells become circulating tumor cells. 
 
     Next, in vivo tumorigenecity was evaluated by limited dilution assays in 
immunocompromised mice. We observed that loss of NQO1 reduced tumor burden and 
increased the overall survival of mice (Chapter 2, Fig. 5C-E). In an effort to better 
determine how NQO1 is affecting the tumorigenic potential of NSCLC cells, we 
evaluated the activity of known CSC marker ALDH. Surprisingly, we found significant 
loss of ALDH activity following depletion of NQO1 (Chapter 2, Fig. 6). These results 
demonstrate that NQO1 may be promoting tumor formation by enhancing the CSC 
population.  This is the first report, to our knowledge, that ties the expression of NQO1 
to the activity of a known CSC marker in any cancer type.  
 
     The data presented in Chapter 2 is the first report in which NQO1 is evaluated for it’s 
pro-tumorigenic role in the establishment of NSCLC. For the first time, NQO1 is 
described as having an integral role in the formation, and progression of cancer. While 
much has been done to target NQO1 due to its overexpression, our data provide the 
first evidence that there may be alternative approaches to targeting tumor NQO1 levels, 
mainly through the use of RNA interference (RNAi) technologies. RNAi technology has 
been utilized previously, however only now has its clinical implications come to light. 
Clinical application of this approach does not come easy however, as there are many 
issues that exist with stability, delivery, and safety (247). Despite these current 
roadblocks, continued research in this field furthers the application daily. This technique 
could be a worthwhile option to explore, given the results we present herein. Reduction 
of tumor NQO1 levels may work to inhibit further tumor growth, as well as the ability of 
cells to survive during periods of detachment. Regardless of the known limitations of 
this approach, the possibility of designing novel useful therapeutics will continue to be of 
significant benefit to patients battling this grave disease. 
 
     Our results depicted in Chapter 2 drove us to further investigate the role that NQO1 
plays in maintaining the CSC population within NSCLC. Observing the loss of ALDH 
activity following depletion of NQO1 expression indicated that NQO1 might be altering 
the CSC population in NSCLC. CSCs have been reported to be responsible for tumor 
recurrence, resistance, and metastasis, and therefore further investigation into the role 
NQO1 was playing to support this population was warranted (248). In order to 
investigate this possibility, we utilized a number of well-established CSC assays, and 
demonstrated that loss of NQO1 leads to a decrease in the prominence of the CSC 
population. 
 
     Inquiry into NQO1 functioning to support the CSC phenotype began with evaluation 
of in vitro tumor sphere formation. The spheroid assay evaluates the tumor initiating 
capabilities of a cell population. Transformed cells are defined by the ability to survive 
and proliferate in an anchorage-independent manner, as demonstrated by this assay 
(249). In addition, the media utilized contains ultra-low levels of fetal bovine serum 
(0.25%) that enhances the stem cell population by reducing the differentiation of stem 
cells to their progenitors (57). Upon evaluation of the A549 and H358 NSCLC cell lines, 
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we determined that reduction of NQO1 led to a significant decrease in the ability of 
these populations to form spheroids. This result indicated that NQO1 was supporting 
the growth and expansion of the NSCLC stem cell population (Chapter 3, Figure 2). 
 
     Spheroid formation demonstrated an enrichment in the CSC population in those lines 
with their complete compliment of NQO1, however it is of paramount importance to 
demonstrate self-renewal when attempting to demonstrate the presence of a CSC 
population (250). To do so, primary spheroids where dissociated, both mechanically and 
enzymatically, and plated into secondary spheroid assays, followed by tertiary plating. 
In all scenarios, it was demonstrated that loss of NQO1 led to decreased spheroid 
numbers, indicating that NQO1 is playing a supportive role in maintaining the CSC pool 
within NSCLC (Chapter 3, Figure 4). Futhermore, we established NQO1 re-expression 
in our A549-shNQO1 cell line, as well as the NQO1-null cell line H596, and 
demonstrated a significant increase in the number of spheroids formed in comparison to 
controls (Chapter 3, Figure 4C,D & Figure 5). 
 
     In order to quantify the number of tumor initiating CSC within our populations, we 
employed the in vitro extreme limited dilution assay (ELDA). The ELDA assay functions 
similarly to the spheroid assay, but utilizes limiting dilutions of cells, and software 
(available at http://bioinf.wehi.edu.au/software/elda/), to calculate the number of CSCs. 
The results from this assay demonstrated a greater than 10-fold enrichment in the A549 
cell lines, as well as a doubling of the CSC population between the H358-shCtr and 
H358-shNQO1 cell lines. In addition, there was a greater than 30-fold enrichment 
between the A549-shCtr and H358-shCtr cell lines (Chapter 3, Table 1). This correlates 
well with an increase in the sphere forming abilities of the A549 cell line versus that 
which is seen in the H358 cell line (Chapter 3, Figure 2). The results of the ELDA 
assay, spheroid formation, and NQO1 rescue experiments strongly back a supportive 
role for NQO1 in the CSC population of NSCLC. 
 
     Finally, we evaluated the chemotherapeutic resistance of NQO1 knockdown cells 
versus controls cultured as spheroids. CSCs are believed to be responsible for 
therapeutic resistance (18, 44, 87), and it is of great importance to demonstrate this trait 
when describing a CSC population. NSCLC spheroids were dissociated after two weeks 
in culture and plated as single cells. This assay was carried out in this manner to evenly 
treat all cells found within the spheroid. The spheroid model has been utilized as a drug 
treatment model of micrometastasis, and functions to determine the diffusion limit of 
drug across an avascular tumor (251). In addition, the CSC population has been 
described to be centrally located within these spheroids and thus protected from drug 
treatment (252). Single cell suspension was the only method by which to treat all cells of 
the spheroid in an unbiased manner. A549 and H358-shCtr cells, treated for 24 hours 
with increasing doses of cisplatin, displayed an increased survival over their NQO1 
knockdown counterparts (Chapter 3, Fig. 6). These results demonstrated that NQO1 








     Lung cancer continues to be the leading cause of cancer related deaths in the world 
(2). This trend continues in spite of attempts to decrease lung cancer risk with 
approaches such as smoking cessation. Declines in the percentage of the smoking 
population in recent history 
have yet to result in 
significant decreases in lung 
cancer incidence (Figure 1) 
(253). These observations 
indicate that there are other 
contributors to the formation 
of lung cancer besides 
smoking, an example being 
pollution (254). Regardless of 
the extrinsic factors that are 
influencing lung cancer 
development, it is paramount 
to research and develop new 
approaches to treating those 
patients with the disease. 
 
     The modern age of anti-
cancer therapy has gone 
personal. The idea of personalized medicine is one in which many believe is the future 
of cancer therapy (255, 256). Unveiling and understanding both new and old cancer-
promoting pathways will reveal targets toward which to design new medications in an 
effort to thwart pro-tumorigenic signaling. A major shortcoming with this approach 
however, is the high rate of refractory disease (257). The eventual ineffectiveness of 
targeted drugs requires that secondary and tertiary lines of therapy be developed in an 
effort to prolong the positive response. 
 
     The CSC population is a unique population of cells that exist within each tumor 
purportedly having unique abilities including therapeutic resistance, the ability to seed at 
distant metastatic sites and to cause relapse of disease (32). The CSC populations 
have become highly researched due to the belief that obliteration of this population will 
lead to total eradication of tumors (258). In principal this idea is simple, but in practice it 
is quite the challenge. Currently, there are few therapies that are targeted toward CSCs, 
and often those therapies are ineffective or toxic to the patient (259, 260). An obvious 
major roadblock to CSC targeted therapy is the utilization of markers that are also 
present on somatic stem cells throughout the body (261). Eliminating the CSC 
population has the very real potential to have an off-target effect on the somatic stem 
cell population (262). From this perspective, it becomes clear that CSC targeted 
therapies must target pathways, or markers, that are specific to cancer. 
 
Figure 1. Comparison of the percentage of the smoking population and 
NSCLC incidence rates. Over time, the percentage of the population of 
individuals that smoke continues to drop in the United States (blue bars) 
however, the rate of lung cancer incidence remains steady (grey bars). 
Smoking percentage data was collected from The National Health Interview 
Survey, 1965-2014 available at 
http://www.cdc.gov/tobacco/data_statistics/tables/trends/cig_smoking/index.ht
m. NSCLC incidence rate data was collected from the SEER database.	
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     NQO1 has repeatedly been demonstrated to be overexpressed in tumor in 
comparison to normal tissues (116, 122). This has lead to the development of NQO1 
targeted therapy that has progressed to clinic (263). This dissertation presents data that 
fills in the void on NQO1’s role in NSCLC. We demonstrate that the up-regulation of 
NQO1 observed in tumors promotes the tumorigenic characteristics and progression of 
disease (Chapter 2).  Additionally, we show a novel role for NQO1 in the maintenance 
of the NSCLC CSC population (Chapter 3). These findings are important and impactful 
for a number of reasons including 1) furthering the understanding of NQO1’s 
mechanism of action in the promotion of NSCLC and 2) defining a novel stem cell 
maintenance pathway. The results presented here provide the groundwork for future 
studies that delve deeper into the workings of NQO1 as a tumor-promoting factor, and 
argue that pharmaceutical approaches to reducing the tumor expression of NQO1 may 
be a viable therapeutic strategy. Given that we demonstrate NQO1 to have a positive 
role in supporting the CSC population, as well as tumor progression, the utilization of 
therapies to reduce NQO1 expression, such as RNAi technology, could provide 
clinicians with a two-headed approach; one that can stop cancer at the source, and 










     Our investigation into the role of NQO1 in tumorigenesis and maintenance of the 
CSC population has utilized gene manipulation via short hairpin RNA (shRNA) 
technology. shRNA has provided investigators the ability to alter gene expression 
through the specific targeting of messenger RNA encoding their gene of interest (264). 
The formation of double stranded RNA through the binding of shRNA to the target 
mRNA, leads to the destruction of both 
the message and shRNA, thus 
reducing the expression of protein 
(265) (Figure 1A). The use of this tool 
has unveiled numerous discoveries, 
however the technology does not allow 
for the complete elimination of protein 
expression. In an effort to better 
understand the role that NQO1 plays, 
utilization of the CRISPR-Cas9 system 
was incorporated into our ongoing 
studies. CRISPR-Cas9 allows for 
direct alteration of the genome that 
results in the complete loss of protein 
expression (266) (Figure 1A). For 
these reasons we employed the 
CRISPR-Cas9 system in our A549 
NSCLC cell line in order to determine 
the phenotypic effects of total NQO1 
protein loss. 
 
     Studies were initiated with 
transfection of the lentiviral CRISPR-
Cas9 system containing the small 
guide RNA (sgRNA) toward NQO1 into 
the A549 cell line (Figure 1B). 
Following selection with puromycin (2 
µg/ml), cells were plated in limited 
dilution in order to acquire single cell 
clones that were subsequently 
expanded. Once expanded, Western blot analysis was utilized to determine which, if 
any, clones had lost NQO1 expression. We discovered two successful NQO1 knockout 
clones (A549 C-NQO1 1 and A549 C-NQO1 2) as determined by Western blot, and 
Figure 1. CRISPR-Cas9 genetic knockout of NQO1 in the 
A549 cell line. In A, model demonstrating shRNA targeting of 
NQO1 leads to residual protein expression. Implementation of 
CRISPR-Cas9 technology will allow for complete resolution of 
NQO1 protein expression. In B, outline of small-guide RNA 
(sgRNA) designed to target NQO1 utilizing the CRISPR-Cas9 
system. PAM sequence highlighted in red. In C, Western blot 
analysis of NQO1 expression in two CRISPR-Cas9 NQO1 
knockout clones (A549 C-NQO1 1 and A549 C-NQO1 2). A549 
served as a positive control and H596 served as an NQO1-null 
control. In D, complete loss of functional NQO1 activity was 





subsequent sequencing (Figure 1C, Supplemental Figures 1-2). We then performed 
an NQO1 activity test in order to confirm loss of protein activity (Figure 1D). It was 
determined that there was no significant difference in NQO1 activity between the 
parental A549 cell line (A549) and the CRISPR-Cas9 control (A549 C-Ctr), however 
there was complete loss of NQO1 activity in the A549 C-NQO1 1 and A549 C-NQO1 2 
cell lines. Absence of activity was confirmed by comparison to the NQO1*2 cell line 
H596, which is known to lack functional NQO1. These results demonstrate that 
utilization of the CRISPR-Cas9 system resulted in the creation of A549 NQO1-null cell 
lines, the first of their kind to our knowledge. 
 
     We next investigated the effect of 
complete NQO1 loss in a number of 
assays that we have previously 
employed. These included spheroid 
formation, soft agar colony formation, 
and drug resistance. Surprisingly there 
was no significant difference in the 
number of spheroids (Figure 2A & B) 
or colonies formed (Figure 2C & D). 
Additionally, no alterations in resistance 
to the platinum based chemotherapy 
cisplatin were noted between our A549 
C-Ctr and C-NQO1 knockout cell lines 
(Figure 2E). These results were 
surprising given that our results with 
shRNA-NQO1 knockdown in A549 cells 
led to a significant decrease in all of 
these assays. In order to account for 
this difference, we compared the 
differences between the two methods. 
We concluded one method (shRNA) 
directly targets mRNA, whereas the 
CRISPR-Cas9 approach directly edits 
the genome and may result in the 
production of a non-translatable mRNA. 
This understanding led us to 
hypothesize that it is not NQO1 protein, 
but the NQO1 mRNA that is responsible 




Figure 2. NQO1 knockout has no effect on spheroid 
formation, soft agar colony formation, or cisplatin 
resistance. In A, A549 NQO1 knockout clones (A549 C-NQO1 
1 and A549 C-NQO1 2) were placed into a spheroid assay, and 
after two weeks the number of spheres were quantified. In B, 
representative images of spheroids formed in A. In C, Knockout 
clones were also placed into soft agar colony formation, where 
there was no significant difference in the number of colonies 
formed between the NQO1 knockouts and control. In D, 
representative images of soft agar colony formation. In E, NQO1 
knockout clones were treated with 0, 2.5, 5, and 10 µM cisplatin 
for 24 hours and evaluated for viability utilizing the Cell-titer Glo 





     We first 
evaluated the 
expression of 
NQO1 mRNA in 
our A549 C-
NQO1 cell lines 
(C-NQO1 1 and 
C-NQO1 2) 
versus the A549 
C-Ctr. Results 
demonstrated 
that there was 
no alteration in 
the expression 
of NQO1 mRNA 




(Figure 3A) In 
an effort to 
reduce the 
expression of 
NQO1 mRNA in 
the A549 C-
NQO1 1 cell line, we transiently knocked down the mRNA levels using siRNA directed 
toward NQO1. Significant reduction in the expression of NQO1 mRNA was achieved in 
both the A549 C-Ctr and C-NQO1 1 cell lines, as determined by real-time qRT-PCR 
(Figure 3B). We next evaluated the sphere forming ability of the cells treated with 
siRNA toward NQO1 (A549 C-NQO1 1 siNQO1) versus the scrambled control (A549 C-
NQO1 siCtr). Results demonstrate a significant decrease in the sphere forming ability, 
of those cells treated with siRNA toward NQO1 (Figure 3C). Additionally, when 
measuring the size of spheres formed, a significant decrease in sphere area was 
observed in the siRNA treated cells versus those treated with control.  
 
     These results are the initial demonstrations of a novel role for NQO1 mRNA, the 
regulation of the CSC phenotype in NSCLC. While these results are preliminary, they 
provide enough support to postulate a mechanism by which the NQO1 mRNA is playing 
a signaling role in NSCLC. We hypothesize that NQO1 mRNA is acting as a micro-RNA 
(miR) sponge for a possible number of known CSC associated miRs, including the Let-7 
family, miR-34a, and miR-143 (267-269). (Figure 4A)  Reduction of the listed miRs has 
been demonstrated previously to result in an increase in the CSC phenotype that would 
coincide with our observation that reduction of NQO1 mRNA results in decreased 
prominence of the CSC phenotype, possibly thorough the liberation of the listed miRs 
(268, 270, 271). (Figure 4B) In addition, the miRs listed have been predicted to bind to 
NQO1 mRNA according to the prediction software available at www.targetscan.org. 
  
	
Figure 3. CRISPR-Cas9 knockout 
clones produce NQO1 mRNA, and 
its reduction inhibits spheroid 
formation. In A, NQO1 knockout 
clones were evaluated for NQO1 
mRNA expression via real-time 
qRT-PCR, and demonstrate no 
difference in transcript levels in 
comparison to controls. In B, 
transient knockdown of NQO1 
mRNA was successfully achieved 
by using siRNA directed at NQO1, 
and validated using real-time qRT-
PCR. In C, A549 C-NQO1 1 siCtr 
and siNQO1 cell lines were placed 
into the spheroid assay, and 
quantified. A statistically significant 
difference in spheroid formation was 
noted (* = p = 0.016). In D, the area 
of the siCtr and siNQO1 spheroids 
was evaluated and a significant 
reduction in sphere area was 
observed (* = p = 0.0161). In E, 
representative images of spheroids 
formed in both A549 C-NQO1 1 




Future studies will be necessary in 
order to confirm the relationship of 
NQO1 mRNA with that of the listed, 
and possibly greater numbers of miRs. 
  
     These results implicate the NQO1 
message as having a crucial role in 
the maintenance of the CSC and 
transformed phenotype of NSCLC. In 
addition these results support our 
previous proclamation that therapies 
focused on reduction of NQO1 may 
serve useful in clinic. The application 
of RNAi technology to reduce 
expression in patients may provide 
increased survival and better 
prognosis through the lessening of the 
pro-tumor effects demonstrated by the 
expression of NQO1. 
  
Figure 4. NQO1 mRNA may function as a miR sponge and 
promote the CSC phenotype. In A, schematic of possible NQO1 
mRNA mechanism in regulating the CSC phenotype. Classically, 
NQO1 mRNA is transcribed and then translated into a functional 
protein. Preliminary data suggests that NQO1 protein expression 
and activity is not responsible for its promotion of the CSC 
phenotype, as complete loss does not abolish the CSC traits that 
are apparent when NQO1 protein is present. Instead, we propose 
that NQO1 mRNA is playing a functional role by acting as a miR 
sponge to inhibit the actions of miRs known to be involved in the 
CSC phenotype, such as the let-7 family, miR-34a, and mIR-143 . 
In B, a model showing demonstrating NQO1 mRNA expression 
leads to a decrease in miRs that result in the emergence of the 




Supplemental Figure 1. Sequencing validation of C-NQO1 1 CRISPR-Cas9 
mediated knockout of NQO1. In A, BLAST sequence alignment of C-NQO1 1 (subjct) 
demonstrating a 26 nucleotide deletion, in comparison to the control (query), in one 
NQO1 allele. In B, sequencing histogram illustrating the 26 nucleotide deletion seen in 
A. In C, BLAST sequence alignment of C-NQO1 1 (subjct) demonstrating a 9 
nucleotide deletion, in comparison to the control (query), in the second NQO1 allele. In 




.    
Supplemental Figure 2. Sequencing validation of C-NQO1 2 CRISPR-Cas9 mediated 
knockout of NQO1. In A, BLAST sequence alignment of C-NQO1 2 (subjct) 
demonstrating a 10 nucleotide deletion, in comparison to the control (query), in one NQO1 
allele. In B, sequencing histogram illustrating the 10 nucleotide deletion seen in A. In C, 
BLAST sequence alignment of C-NQO1 1 (subjct) demonstrating a 17 nucleotide deletion, 
in comparison to the control (query), in the second NQO1 allele. In D, sequencing 
histogram illustrating the 17 nucleotide deletion seen in C. 	
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Materials and Methods 
 
Cell Culture 
     A549, A549 C-NQO1 1, A549 C-NQO1 2, and H596 cell lines were grown in 
Dulbecco’s Modified Eagles Media (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and 1% L-glutamine. Cell lines were cultured at 37° C with 20% oxygen and 5% 
carbon dioxide prior to spheroid culture. Cells were passaged weekly and supplemented 
with fresh media. 
 
Western blotting 
     Protein lysates were separated by 10% SDS-PAGE and transferred onto a PVDF 
membrane. Membranes were blocked with 5% milk in PBST for 1 hour at room 
temperature, and then incubated overnight with β-actin (1:5000, Santa Cruz 
Biotechnology) at 4°C. Blots were washed in PBST and incubated for 1 hour with 
1:5000 dilution of goat-antimouse IgG-HRP in 5% milk in PBST. The process was 
repeated using a 1:5000 dilution of monoclonal NQO1 antibody (clone A-180, Santa 
Cruz Biotechnology), SOX2 (1:1000, Cell Signaling), Shh (1:1000, Cell Signaling), Oct-4 
(1:1000, Cell Signaling), and Nanog (1:1000, Cell Signaling). Pierce ECL western 
blotting substrate (Thermo Scientific) was used to visual bands on Hyblot-CL 
autoradiography film (Denville Scientific) 
 
NQO1 Activity Assay 
     NQO1 enzyme activity was performed as previously described. (144) Briefly, 2x107 
cells of each cell line were collected. Pellets were solubilized in extraction buffer for 20 
min, after which they were centrifuged at 18,000 x g for 20 min at 4° C. Supernatants 
were collected into eppendorf tubes at stored at -80° C. Samples were then run 
according to the manufacturers protocol for the NQO1 activity assay kit from Abcam. 
Results were read at an absorbance of 440 nm every 20 seconds for 5 minutes utilizing 




     CRISPR targeting sequences toward NQO1 were generated using the available 
software from crispr.mit.edu. The sgRNA guide sequences that were designed were: 
NQO1: 5’-CACCGCAGAAGAGCACTGATCGTAC-3’ and 5’-
AAACGTACGATCAGTGCTCTTCTGC-3’. The lentiCRISPRv2 backbone was digested 
and dephosphorylated using the BsmBI restriction enzyme and gel purified using the 
QIAEX II Gel Extraction Kit. (Qiagen) The sgRNA guides were then annealed and then 
ligated with the purified plasmid. Stbl3 bacteria were then transformed with the plasmid 
via heat shock and plated on carbenicillin containing agar. Colonies were selected and 
a mini-prep (Qiagen) was performed. Samples were then cut and run on an agarose gel 
in order to determine sequence insertion. Promising clones were then sequenced. 
Clones containing the insert were then maxi-prepped and collected plasmid was used to 
transfect Phoenix 293T cells. Media containing the lentiviral particles was then collected 




     In order to generate NQO1 knockout cell lines, the lentivirus-containing media was 
added to cells at a 1:1 ratio with fresh 10% FBS DMEM. The virus was allowed to 
incubate with the cells for 24 hours after which they began to undergo selection. 
Selection was carried out using 2 ug/ml puromycin over a minimum period of two 
weeks. Following recovery from selection, the cell lines were placed into limited dilution 
and single cell clones were chosen for expansion. Selected clones were then evaluated 
via Western blot for NQO1 expression and subsequently sequenced to confirm NQO1 
disruption.   
 
Spheroid Formation 
     Low attachment cell culture plates (Corning) were produced by coating the plates 
with a 0.2% poly-hema/95% ethanol solution. Plates were incubated at 60° C overnight 
and allowed to dry. The process was then repeated a second time. Plates were washed 
twice with milli-Q water immediately prior to use. 
 
     Cells were trypsinized and treated with trypsin neutralizing solution (1:1 ratio) prior to 
being counted using a hemacytometer. 10,000 were then plated in the low attachment 
100 mm plates in 0.25% FBS DMEM supplemented with 1% L-glutamine. Cells were 
allowed to form spheroids over 14 days, at which time they were collected, trypsinized 
into single cell suspensions, and utilized for future assays 
 
. Drug Treatment Studies 
     Spheroids were collected after 14 days and trypsinized into single cell suspension. 
Cells were counted and suspended in DMEM media supplemented with 0.25% FBS and 
1% L-glutamine at a concentration of 10,000 cells/ml. 200 ul of cell suspension was 
then added to each well. Cells were allowed to attach overnight, and the following day 
were treated with 0, 2.5, 5, and 10 uM cisplatin dissolved in DMSO. Stock 
concentrations of 2.5, 5, and 10 mM cisplatin were diluted 1:1000 in 0.25% FBS DMEM 
supplemented with 1% L-glutamine and incubated on cells overnight. Each dose was 
performed in 8 replicates for each dose tested. Twenty-four hours after initial treatment, 
cell viability was assessed using Cell-Titer Glo (Promega), according to the 
manufacturer’s protocol utilizing the Synergy-H1 Hybrid Reader. 
 
Transient and stable NQO1 mRNA knockdown assays   
     The human shRNA-NQO1 retroviral vector was purchased from Open Biosystems. 
The stable shRNA knockdown cell line (A549 C-NQO1 shNQO1) was generated by 
infecting A549 C-NQO1 cells with polybrene-supplemented medium obtained from 
Phoenix packaging cells transfected with the human retrovirus vector targeting NQO1 
as described previously (168). Medium was changed 24 hours after transfection. After 
48 hours shNQO1 containing cells were isolated by limited dilution in media containing 
puromycin (2 µg/mL) and screened for NQO1 mRNA expression levels by real-time 
qRT-PCR. For transient NQO1 knockdown, siRNA-NQO1 or scramble control siRNA 
(Santa Cruz Biotechnology) was transiently transfected into HCC1171 cell lines 
(Lipofectamine 2000, Life technologies) using the Life technologies protocol. Cells were 




Anchorage independent growth assays 
     A 1.5% SeaPlaque Agarose (SPA) mixture was made by slowly adding SPA to PBS 
and autoclaving. 0.5% SPA was created by diluting the 1.5% stock SPA 1:3 with culture 
media. 1 mL of the 0.5% SPA mixture was added to each well of a 6 well plate to create 
a bottom layer and allowed to solidify at room temperature for 15-20 minutes. Cells 
were counted and suspended at 750 cells/mL in a separate 0.5% SPA mixture. 2 mL 
were added to each well on top of the bottom layer and allowed to solidify for 30-45 
minutes at room temperature to create a cell layer. A 0.3% SPA mixture was created by 
diluting the 1.5 % stock SPA 1:5 with culture media. 1 mL of the 0.3% SPA mixture was 
added to each cell layer and allowed to solidify for 20-30 minutes at room temperature 
to create a top layer. 250-500 µL of culture media was added onto the top layer to 
prevent from drying out. Plates were wrapped in parafilm and placed at 37°C. 250-500 
µL of new culture media was added every week. Plates were imaged after 3 weeks 
using and Epson V700 photo scanner. The enumeration of colonies present in each 










     The expression levels of NQO1 have long been shown to be elevated in a number of 
malignancies, in comparison to their normal controls (116). This increased expression 
has led to the targeting of NQO1 through the utilization of NQO1 bioactivateable drugs 
(170, 174). While the bulk of research has focused on improving NQO1 targeted 
therapies, there has been very little done to determine the functional role of NQO1 in 
the cancer cell. The work presented here aimed to fill in the void of NQO1’s function in 
malignancies by evaluating a number of tumorigenic properties. We demonstrated that 
NQO1 was vital for anchorage independent growth, anoikis resistance, invasion, ROS 
regulation, tumor growth, and ALDH activity. The alteration of a known CSC marker’s 
activity drove us to investigate NQO1’s role as a possible CSC marker. 
 
     Our investigations into NQO1 as a CSC marker led to some quite interesting results. 
We were able to demonstrate that loss of NQO1 led to a decrease in spheroid 
formation, in both primary and serial spheroid cultures. In addition, we show that 
spheroid cultured A549-shCtr cells have increased drug resistance and proliferation. 
These results strongly support NQO1 as a major supporter of the CSC phenotype. 
Additionally we argue that reduction of NQO1 in patient tumors may be a useful strategy 
in eliminating the CSC population. 
 
     Finally, we investigated the effect of total loss of NQO1 through the implementation 
of the CRISP-Cas9 system. To our surprise, complete loss of NQO1 did not affect 
sphere formation, soft agar colony formation or the drug resistance that was observed in 
our shRNA-NQO1 knockdown studies (Chapter 2). In an effort to determine if NQO1 
mRNA was involved, a transient knock down of NQO1 mRNA by utilization of RNAi 
technology was implemented. The transient reduction of NQO1 mRNA led to a 
decrease in spheroid formation indicating NQO1 mRNA may be involved in maintaining 
the transformed phenotype. These data also present the possibility that NQO1 mRNA is 
a contributing factor in our previously published work (Chapter 2).  
 
     The future focus of this project should center on NQO1 mRNA and the mechanism 
by which it is affecting both the transformed phenotype, and the CSC population. It has 
been shown previously that a number of miRs are capable of altering the CSC 
population. Additionally, the mechanism by which mRNA functions as a miR sponge has 
been well documented (272-274). Given that reduction of these purported miR leads to 
an increase in the CSC phenotype, the hypothesis that NQO1 mRNA is acting as a miR 
sponge would align with these observations.  
 
     Future efforts will need to be made in order to determine the miRs that are capable 
of binding to NQO1 mRNA, and whether or not NQO1 mRNA can function as a suitable 
mRNA sponge. Some techniques that may be utilized in this effort include RISC 
complex immunoprecipitateion, HITS-CLIP, PAR-CLIP, and labeling of miRs or mRNA 
in order to perform immunoprecipitation (275-277). Given the massive effort being put 
forth into identifying and validating miRs, validating those that associate with NQO1 
mRNA will provide future work with a solid foothold on which to build an understanding 
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of the mechanism of NQO1 mRNA regulation of tumorigenesis, as well as the cancer 
stem cell population. Validation of the role of NQO1 mRNA in tumorigenesis can 
ultimately lead to development of clinically relevant drugs that target this mRNA, the 
miRs it regulates, or downstream pathways that may be driving these tumors.  
 
     Finally, investigation of NQO1 mRNA expression and its inhibition in tumors that 
have an NQO1 polymorphism may explain why those tumors lacking functional NQO1 
protein may still be capable of forming tumors. To our knowledge there are no 
exhaustive investigations into the expression of NQO1 mRNA in polymorphic tumors 
tumors, however moderate mRNA expression has been reported in polymorphic cell 
lines (134, 278).It would be interesting to evaluate the mRNA expression in polymorphic 
cells and demonstrate that reduction of NQO1 mRNA results in an attenuated 
tumorigenecity. In closing, there is an unknown amount of information that has yet to be 
revealed pertaining to NQO1. Previous work on NQO1 mainly focused on utilizing 
bioactivateable drugs to specifically target NQO1 over-expressing tumor cells. The 
future of NQO1 research should focus more on NQO1’s pro-tumorigenic role, as protein 
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